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Foreword	to	the	thesis	
	
by	Dr.	Pawel	K.	Olszewski,	Chief	Supervisor	of	Oscar	A.	Klockars’	doctoral	project	
 
Oscar Klockars was a PhD student at the Faculty of Science and Engineering at the 
University of Waikato from September 2014 until his untimely passing in September 
2018. This doctoral thesis represents the first draft of the document that Oscar 
provided to the supervisory team. 
Prior to joining the University of Waikato as a PhD student, Oscar graduated from the 
Örebro University in Sweden with a Masters degree in medicine. In Sweden, he 
acquired broad theoretical knowledge of molecular processes that underlie proper 
physiological functioning of the organism as well as those that lead to pathological 
states. He gained significant research experience by performing his Masters thesis 
work in the clinical molecular microbiology laboratory (that project led to his being a 
co-author of a scientific report entitled ‘Pharmacodynamic studies of nitrofurantoin 
against common uropathogens’ published in Journal of Antimicrobial 
Chemotherapy), and by doing a long-term internship with Prof. Dan Larhammar’s 
neuropharmacology group at Uppsala University.  
Oscar’s substantial expertise was crucial in his being able to jumpstart a series of 
successful experimental research projects at the University of Waikato. He was 
independent in formulating hypotheses and in devising practical strategies to tackle 
scientific questions. Over a relatively short time period, not only did Oscar master 
the advanced skills involving intracranial surgeries, in vivo pharmacology, and brain 
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activation analyses, but he also incorporated a number of previously learned 
methodologies, and single-handedly developed approaches allowing him to record 
select complex behaviors of laboratory animals.  
Oscar generated a large body of data during his doctoral work. These data are a part 
of this PhD thesis, and have been the basis of three research publications. The first 
report, ‘Central oxytocin receptor stimulation attenuates the orexigenic effects of 
butorphanol tartrate’ (Olszewski PK, Klockars OA, Klockars A, Levine AS; Neuroreport; 
2016; 4 citations) showed that a satiety mediator, oxytocin, is able to decrease 
extreme overeating induced pharmacologically by a potent, mixed opioid receptor 
ligand, butorphanol. It was an important discovery from the standpoint of expanding 
limited tools to alleviate excessive appetite induced by agonism of opioid receptors. 
In the second paper, ‘Neural basis of ventromedial hypothalamic oxytocin-driven 
decrease in appetite’ (Klockars OA, Waas JR, Klockars A, Olszewski PK; Neuroscience, 
2017; 5 citations), Oscar determined that oxytocin acting via a discrete hypothalamic 
site regulating energy metabolism, the ventromedial hypothalamic nucleus, 
decreases interest in consumption of highly caloric diets (although this effect is 
unrelated to the flavor of these foods). He defined widespread changes in brain 
activation patterns following this pharmacological treatment and identified relevant 
gene expression changes. In the most recent publication (Oxytocin administration in 
the basolateral and central nuclei of amygdala moderately suppresses food intake. 
Klockars OA, Klockars A, Levine AS, Olszewski PK. Neuroreport. 2018; 3 citations), 
Oscar reported for the very first time that two specific portions of the amygdala, its 
basolateral and central nuclei, mediate satiating properties of oxytocin in the context 
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of terminating consumption of high-energy foods. He also determined that the 
basolateral nucleus, which belongs to the network of sites that regulate emotional 
processing of behaviors, including eating behavior, promotes cessation of 
consumption of non-caloric and low-calorie palatable fluids via its oxytocin receptor. 
Overall, Oscar’s findings make a tremendous contribution to our understanding of 
neural mechanisms through which oxytocin reduces appetite and of aspects of food 
intake (eating for energy versus eating for pleasant taste) affected by oxytocin acting 
via distinct brain areas. 
Oscar’s accomplishments were possible thanks to his fantastic rapport with staff and 
fellow students at the University. His respectful and kind attitude, his willingness to 
discuss research progress, offer and accept advice, being a team player unafraid of 
taking responsibility upon himself, made him a truly valued member of our 
community and the person with whom we enjoyed working and interacting daily.  
I would like to take this opportunity and thank the members of the supervisory team, 
Prof. Joseph Waas and Dr. Steve Bird. In my conversations with Oscar, it was certain 
that he felt genuine support from both Joe and Steve, and he greatly appreciated 
their willingness to share professional expertise and provide guidance and advice not 
just on research, but also on personal matters. 
In the lab, Oscar was surrounded by colleagues and friends who shared his passion 
for science and contributed alongside him to creating the pleasant and supportive 
atmosphere: Anica Klockars, Kerry Allen, Sarah Gartner, Erin Wood, Mitch Head, 
Florence Herisson, Laura McColl, Fraser Aidney, Kathryn Laloli, Kiriana Isgrove, Cushla 
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Moscrip, Moh Arafat, Chloe Brunton, and Tiffany Fehlmann. Thank you all for 
accompanying Oscar on his journey toward completing his doctoral research. 
Finally, I would like to express my gratitude to Oscar’s family. There is no surprise 
that two wonderful, loving children, Heidi and Rocky, were the most important 
‘project’ that Oscar and Anica shared. The love for the children helped Oscar tackle 
all the challenges encountered on his research path, it served as the most welcomed 
and endearing distraction, and it filled his life with purpose, hope and joy. Oscar’s 
family in Sweden, his Mom, Dad and siblings, were always the source of support, 
willing to talk to Oscar, listen to him, and provide him with advice and loving words 
whenever needed. 
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Abstract	
Recent years have brought exciting discoveries showing that a neurohormone, 
oxytocin (OT), acts as an appetite suppressant. Importantly, OT decreases energy 
needs-driven consumption of high-calorie foods by promoting early satiation, and it 
terminates intake motivated by palatability related to sweet taste. OT’s anorexigenic 
effects on both aspects of ingestive behavior are mediated by the OT receptor (OTr) 
expressed broadly in the brain, however, our understanding of which specific sites 
relay anorexigenic actions of OT is limited. Thus far, only the nucleus accumbens and 
ventral tegmental area of the mesolimbic system, and the brainstem’s dorsal vagal 
complex, have been directly implicated in relaying OT-induced hypophagia. Thus, the 
overarching goal of this thesis was to examine which discrete components of circuitry 
expressing the OTr mediate OT’s anorexigenic effects on energy- versus reward-
driven feeding. The research approaches included intracranial drug administration, 
analyses of region-specific expression of genes, neuronal activation mapping, and 
feeding behavior testing in rats. 
The first set of studies explored whether extreme overeating induced by a powerful 
orexigen, butorphanol tartrate (BT), can be alleviated by pharmacologically 
stimulating the OT receptor in the forebrain versus the hindbrain (via lateral (LV) and 
fourth ventricular (4V) OT injections, respectively). I established effective doses of BT 
and LV / 4V OT. Then, I determined doses of LV and 4V OT that reduce hyperphagia 
produced by BT in sated and deprived rats. Finally, I assessed whether OT’s effects 
on BT-induced feeding can be suppressed by an OTr antagonist. 4 mg/kg BT increased 
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intake in fed and in deprived rats, whereas LV and 4V OT at 1μg caused a decrease in 
deprived rats. BT-induced chow intake in hungry and sated animals was suppressed 
by a very low, 0.1-μg dose of 4V OT, whereas 1μg OT was effective LV. The effect of 
OT was attenuated by OTr antagonist. The data strongly suggest that while both the 
forebrain and hindbrain populations of the OTr promote hypophagia, the hindbrain 
component of the circuitry is particularly sensitive to appetite reducing properties of 
OT in animals motivated to eat by a potent orexigen, BT. 
In the second set of studies, I examined whether either of the two populations of the 
hypothalamic OTr, in the medial preoptic area (MPOA) or the ventromedial 
hypothalamic nucleus (VMH), mediates OT-driven hypophagia in energy- and 
reward-related ingestive behaviors. I provide insights into mechanisms underlying 
OT-driven anorexia mediated by the hypothalamus by (a) defining whether OT MPOA 
or VMH administration affects feeding for energy versus palatability; (b) identifying 
feeding-related sites activated by VMH OT injection; (c) measuring VMH OTr mRNA 
changes in response to hunger and palatability; and (d) examining how VMH OT 
affects sweet solution intake in rats. MPOA had no effect on intake of energy-dense 
chow in deprived rats nor did it decrease intake of calorie-dilute palatable solutions. 
VMH OT decreased chow intake and the effect was reversed by the antagonist. OT 
did not affect intakes of saccharin and sucrose solutions. Fos immunoreactivity, a 
marker of neuronal activation, was elevated in the VMH and energy balance-related 
paraventricular and arcuate nuclei, but not reward areas. VMH OT receptor 
expression was higher in hungry than sated rats; saccharin intake had no effect. In 
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sum, MPOA OTr is not involved in OT-driven hypophagia mediated by hypothalamic 
networks. VMH OT decreases intake driven by energy not by palatability. 
Finally, I assessed whether the OTr present in the basolateral (BLA) and central 
amygdala (CNA), sites implicated in emotional/pleasure processing of food intake, is 
involved in appetite control by OT. I injected OT in the BLA or CNA and assessed 
intake of chow induced by energy deprivation and intake of sweet solutions in non-
deprived rats. I examined whether these effects are reversible by OTr blockade. I 
determined the effect of energy deprivation and exposure to saccharin on BLA and 
CNA expression of OTr mRNA. BLA OT at 0.3 μg and CNA OT at 1 μg reduced chow 
intake after deprivation. Only BLA OT was effective at suppressing consumption of 
sucrose and saccharin. The anorexigenic effects of BLA and CNA OT were attenuated 
by an OTr antagonist. BLA OTr mRNA expression was affected by exposure to 
saccharin, whereas that of CNA OTr, by energy deprivation. The relationship between 
amygdalar OT and energy- vs palatability-driven intake depends on the discrete 
localization of the OTr in this complex structure.   
Overall, these findings shed light on the specific elements of brain circuitry mediating 
anorexigenic properties of OT. Both the forebrain and hindbrain OTr populations are 
relevant to feeding control. OT’s inhibitory effects on feeding for energy are 
mediated by a broader network of sites that includes, aside from the previously 
reported nucleus accumbens and dorsal vagal complex, the VMH, BLA, and CNA. Only 
the BLA OT modifies eating for reward. Surprisingly, the OTr in the MPOA is not 
involved in feeding regulation.	  
  
8 
Table	of	contents			
1. Chapter One - Introduction and specific aims…………………………….………………11 
 
1.1. Input from the white adipose tissue into the hypothalamus…….…………13 
 
1.2. Key gastrointestinal hormonal input into the hypothalamus………….……17 
 
1.3. Oxytocin peptide and its receptor as anorexigenic components of central 
pathways regulating appetite…………………………………………………………………….22 
 
1.4. Devising aims of the project by identifying critical gaps in knowledge: 
focus on contribution of site-specific populations of the OT receptor to 
appetite control…………………………………………………………………………………………32 
 
1.5. References………………………………………………………………………………………….35 
 
2. Chapter Two - Effects of lateral versus fourth ventricular administration of oxytocin 
receptor ligands on potent orexigenic effects of butorphanol tartrate…………………...56 
  
 2.1 Introduction………………………………………………………………………………..……….57 
 
 2.2. Materials and methods……………………………………………………………………….58 
  
9 
 
 2.3. Results………………………………………………………………………………………………..62 
  
 2.4. Discussion…………………………………………………………………………………………..63 
 
 2.5. Conclusions………………………………………………………………..……………………….65 
 
 2.6. References………………………………………………………………………………………….66 
 
 2.7. Figures and tables…………………………………………………………….…………………69 
 
3. Chapter Three - Anorexigenic potential of oxytocin acting directly in the 
ventromedial hypothalamic nucleus and medial preoptic area………………………………73 
  
3.1 Introduction………………………………………………………………………………..……….74 
 
 3.2. Materials and methods……………………………………………………………………….76 
 
 3.3. Results………………………………………………………………………………………………..82 
  
 3.4. Discussion…………………………………………………………………………………………..84 
 
 3.5. Conclusions……………………………………………………………………..………………….89 
  
10 
 
 3.6. References…………………………………………………………………………………………89 
 
 3.7. Figures……………….………………………………………………………………………………95 
 
4. Chapter Four - Basolateral and central-amygdalar oxytocin moderately suppresses 
food intake………………………………………………………………….………………………………………100 
 
 4.1 Introduction…………………………………………………………….…………………..……101 
 
 4.2. Materials and methods…………………………………………………………….………103 
 
 4.3. Results………………………………………………………………………………………………108 
  
 4.4. Discussion………………………………..……………………………………………………….109 
 
 4.6. References…………………………………………………………………………………..……113 
 
 4.7. Figures and tables……………………………………………………………………..………117 
 5.	Chapter	Five	-	Concluding	remarks………………………………………………………...120	
	 	5.1.	References………………………………………………………………………….……………129	 	
  
11 
1.	Chapter	One	-	Introduction	and	specific	aims	
	
Ingestion of energy is one of the most fundamental functions of all living organisms. 
The vast majority of species have evolved in the environment where sources of 
energy are scarce and, therefore, any opportunity that arises to replenish lacking 
calories should be undertaken. The vast majority of species have not thus evolved to 
be protected from the ‘environment of plenty’. The consequence of our 
evolutionarily conserved adaptation to energy scarcity is that hormonal and neural 
mechanisms that regulate food intake favor avid consumption over feeding 
termination. In fact, the act of feeding termination appears to be quite unique and it 
seems to be reserved to situations in which continued consumption would likely 
result in jeopardized homeostasis. One such circumstance can be ingestion of toxic 
or tainted foods. Neuroendocrine signals that the mediate inhibition of food intake 
are activated immediately after a toxin has been detected by chemoreceptors. 
Similarly, hyperosmolality or extreme levels of stomach distention also lead to 
cessation of eating behavior. Genotypes that have been evolutionarily deemed 
successful are those that are capable of fast acquisition of non-toxic sources of 
calories, boosting energy utilization, and allowing for efficient storage of energy that 
can be engaged upon challenges stemming from low food supplies. Consequently, 
molecules (and their respective genes) that facilitate feeding control are well 
conserved, to the extent that the evolutionary predecessors of many feeding-
relevant peptidergic systems in mammals, arose early in the vertebrate evolution and 
their orthologs can be found even in algae and bacteria  (Schioth, Haitina et al. 2005, 
Scherag, Dina et al. 2010). 
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The hypothalamus is strategically equipped to integrate neural and endocrine 
signaling related to food intake and to execute dynamic changes to energy intake and 
expenditure. Already in the mid-twentieth century, disruption of the ventromedial 
hypothalamic nucleus (VMH) was shown to promote abnormally high feeding (and 
lead to excessive weight gain in a long-term) in rodent models. On the other hand, 
ablations of the lateral hypothalamic (LH) induced anorexia and a decrease in body 
weight (Mayer and Thomas 1967). Disruption of the early development of the 
hypothalamus, including the arcuate nucleus (ARC), in mice by administration of 
monosodium glutamate, led to dysregulated neuroendocrine responses throughout 
the lifespan of these animals and one of the observed phenotypic features was 
hyperphagia and obesity (Olney 1969). During those early years of research on 
hypothalamic control of energy balance, many investigators found that lesions of the 
paraventricular nucleus of the hypothalamus (PVN) and the disruption of the 
hypothalamic-brainstem reciprocal circuit prevented laboratory animals to execute 
termination of feeding that would protect them from pathophysiological 
consequences of extreme overeating (Leibowitz, Hammer et al. 1981, Shor-Posner, 
Azar et al. 1985, Sims and Lorden 1986, Kirchgessner and Sclafani 1988).  
It was several years later that eventually a neurohormone, oxytocin (OT), was found 
to be a crucial feeding-regulatory component of the cytoarchitecture of the PVN as 
well as of the supraoptic nucleus (SON), another hypothalamic site whose projections 
target the neurohypophysis. The broadening array of techniques that could be 
applied to study the functional importance of molecular pathways in behavioral 
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processes, allowed us to better understand that the relationship between the 
hypothalamus (including its OT neuronal populations) and multiple peripheral and 
central mechanisms. It has since become clear that inter- and intra-organ 
communication is the foundation allowing the recognition of the current 
feeding/energy balance status by the organism and shaping a proper consummatory 
response. 
In this introductory chapter, I will first describe integration of peripheral (gut- and 
adiposity-derived) signaling by the hypothalamus, key hypothalamic molecular 
systems involved in energy balance control, and – finally – I will focus on the currently 
available information on the role of hypothalamic OT in feeding control. 
1.1. Input from the white adipose tissue into the hypothalamus  
The discovery of the adipocyte-released hormone, leptin (Lep), encoded by the ob 
gene, was one of the first indicators of how important white fat (and, peripheral, in 
general) signaling is to the ‘assessment’ of the organism’s energy status by the 
hypothalamus (Friedman and Halaas 1998) (though, one should not neglect the fact 
that the current body of evidence implicates also other tissue types in contributing 
to the leptin levels, e.g., the gastrointestinal (GI) tract and urogenital system 
(Sobhani, Bado et al. 2000, Challier, Galtier et al. 2003)).  
The amount of leptin secreted by the fat tissue is equivalent to adiposity (Murphy 
and Bloom 2004). Mice (db) with loss-of-function mutations in the leptin receptor 
(Lepr) gene synthesize are resistant to leptin (Maffei, Fei et al. 1995, Farooqi, 
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Wangensteen et al. 2007). Animals with a knocked-out Lep gene mice are deficient 
in leptin due to the loss-of-function mutation (Zhang, Proenca et al. 1994, Friedman 
and Halaas 1998) and administration of leptin rescues them from overeating and 
excessive body weight (Friedman and Halaas 1998). Peripheral and brain infusions of 
Lepr agonists diminish appetite in wild-type animals (Ahima, Prabakaran et al. 1996, 
Friedman and Halaas 1998).  Rodents subjected to food deprivation and restriction 
show a suppressed Lep expression; refeeding or administration of insulin (which 
serves as the signal for a recently completed meal) reverses this effect on Lep 
receptor levels (Frederich, Lollmann et al. 1995). Finally, knock-in of additional copies 
of the Lepr in the hypothalamus (including in the ARC, PVN and VMH) produces a 
hypophagic phenotype in transgenic animals (Bagnasco, Dube et al. 2002).  
Though for many years it remained a controversial issue, it has now been well 
documented that leptin crosses the blood-brain barrier (BBB) and, upon reaching its 
target neurons, it triggers the JAK2-STAT3 and PI3K-PDE3B-cAMP cellular pathways 
(Mori, Hanada et al. 2004). Distribution of the Lepr in the hypothalamic ARC, VMN, 
DMH and LH is consistent with its role in energy metabolism. Importantly, the Lepr 
is expressed on ARC neurons synthesizing peptides involved in initiation of food 
intake, such as neuropeptide Y (NPY)/Agouti-related protein (AgRP), as well as on 
those that supply anorexigens, for example, cocaine and amphetamine related 
transcript (CART) and proopiomelanocortin (POMC)-derived alpha-melanocyte 
stimulating hormone (alpha-MSH). In vivo pharmacology studies have found that 
alpha-MSH/POMC neurons are stimulated by leptin, whereas AgRP/NPY cells, 
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inhibited by this hormone, which underpins a dual mode of action through which 
leptin suppresses consummatory behavior (Cowley, Smart et al. 2001).  
Adipose tissue synthesizes and releases also another molecule that acts in an 
endocrine fashion at the CNS, adiponectin. The adiponectin receptor is expressed in 
the neurohypophysis, and the hypothalamus, especially in the PVN and ARC 
(Rodriguez-Pacheco, Martinez-Fuentes et al. 2007, Wilkinson, Brown et al. 2007).  
Peripheral administration of this molecule result in an increase in adiponectin 
concentration in the cerebral ventricles, which indicates the ability of the peptide to 
get into the brain tissue (Kubota, Yano et al. 2007). Circulating glucose levels 
determine whether adiponectin excites or inhibits ARC POMC neuronal activity and 
whether the behavioral outcome is associated with initiation or termination of food 
intake (Suyama, Maekawa et al. 2016). ICV co-administration of adiponectin with 
glucose causes hyperphagia, whereas the lack of glucose or its low dose, facilitates 
androgenic action of this adipocyte-derived hormone. Somewhat counterintuitively, 
in vitro studies showed that adiponectin diminishes activity of cells expressing POMC 
when glucose is present, whereas an opposite effect was detected upon removal of 
glucose (Suyama, Maekawa et al. 2016). However, one should note that PONC gives 
rise to not only anorexigens, such as alpha-MSH, but also orexigens, for example, 
beta-endorphin. Furthermore, activity of ARC neurons producing AgRP and NPY is 
inhibited by adiponectin (Sun, Gao et al. 2016), and  adiponectin strengthens 
inhibitory postsynaptic input onto ARC NPY cells to attenuate action potential firing 
in a glucose-independent fashion (Suyama, Lei et al. 2017). 
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One should note that insulin, despite being derived from pancreatic beta cells, is a 
brain-targeting signaling molecule relevant to adiposity. The insulin receptor is 
expressed at high levels in the PVN, ARC, and DMH (Marks, Porte et al. 1990). Fasting 
levels of this hormone parallel the amount of fat tissue (Rocha, Barata et al. 2011). 
Insulin receptor knockout mice display excessive food intake, especially in the 
presence of highly caloric and palatable ingestants, which leads to diet-induced 
obesity. This overeating and obesity are associated with elevated secretion of leptin 
and insulin and with resistance to insulin (Bruning, Gautam et al. 2000). ICV and 
intraparenchymal infusions of this hormone generate cessation of food intake in 
animals under restriction/ deprivation regimens and in sated rodents during the 
natural cycle of night-time consumption (McGowan, Andrews et al. 1992, McGowan, 
Andrews et al. 1992). Third ventricular insulin administration in deprived rats causes 
hypophagia and this outcome was alleviated by subthreshold doses of the synthetic 
antagonist of the MC3/4 receptor, SHU-9119 (thus, a molecule that mimics the 
effects of endogenous AgRP). ARC POMC expression studied with qPCR is also 
elevated after ventricular insulin injections (Benoit, Air et al. 2002). Finally, injections 
of antisense oligodeoxynucleotides against the insulin receptor in the cerebral 
ventricle in rats generate overeating and elevated body weight, and upregulate NPY 
mRNA levels in the ARC, which strongly suggests a functional relationship between 
insulin and NPY circuits in feeding control (Obici, Feng et al. 2002). 
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1.2. Key gastrointestinal hormonal input into the hypothalamus 
Fat tissue-derived signaling tends to pair feeding behavior to the organism’s energy 
state (especially, long-term), whereas the endocrine input into the hypothalamus 
that originates in the GI tract corresponds to feeding/nutritional status of a more 
transient and immediate nature. 
The first identified GI hormone was cholecystokinin (CCK), the endogenous ligand of 
CCK1 and CCK2 receptors (Dufresne, Seva et al. 2006). It is released into the general 
circulation shortly after food reaches the small intestine (Gibbs, Young et al. 1973, 
Buffa, Solcia et al. 1976, Liddle, Goldfine et al. 1985). Peripheral and ICV injections of 
CCK produce undereating in a dose-dependent fashion by reducing meal size 
(Kissileff, Pi-Sunyer et al. 1981, West, Fey et al. 1984) and by inhibiting gastric 
emptying (Castillo, Delgado-Aros et al. 2004, Cummings and Overduin 2007, Jordan, 
Greenway et al. 2008). CCK binds the CCK1 receptor present on hindbrain vagal 
afferents (Noetzel, Stengel et al. 2009), leading to activation of the nucleus of the 
solitary tract (NTS) and dorsal motor nucleus of the vagus (DMNV). Those brainstem 
sites convey this signal into the forebrain, including the hypothalamic PVN and DMH 
(Monnikes, Lauer et al. 1997, Kobelt, Paulitsch et al. 2006, Noetzel, Stengel et al. 
2009). OLETF rats lacking the CCK1 receptor exhibit extreme hyperphagia (Moran, 
Katz et al. 1998, Covasa and Ritter 2001), young OLETF rats that have not yet 
developed obesity, express elevated NPY mRNA levels in the DMH (Moran and Bi 
2006).  
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Enteroendocrine L cells of the intestine release preproglucagon gene products, 
glucagon-like peptides 1/2 (GLP-1/2) and oxyntomodulin, between 10 and 60 
minutes after completion of a meal (Holst 2007). The amount of these hormones 
secreted into the circulation corresponds to the amount of ingested food (Cohen, 
Ellis et al. 2003, Dakin, Small et al. 2004). Injections of these hormones into the brain 
as well as in the periphery produces early termination of feeding (Dakin, Gunn et al. 
2001, Cohen, Ellis et al. 2003). GLP-1 and oxyntomodulin act at ARC cells that express 
the GLP-1 receptor by blocking ghrelin-induced neuronal activation that would lead 
to hyperphagia (Riediger, Eisele et al. 2010). Both peptides induce c-Fos expression 
in the PVN and NTS, and in the PVN, they activate the anorexigenic corticotropin 
releasing hormone (CRH) OT populations (Bojanowska and Stempniak 2000, 
Katsurada, Maejima et al. 2014). 
Intestinal L cells also synthesize peptide YY (PYY), an endogenous ligand of the Y2 
receptor (Halatchev and Cone 2005). The increase in PYY blood levels occurs at the 
end of a meal and it is proportional to the number of consumed calories (Grandt, 
Schimiczek et al. 1994, Batterham, Cowley et al. 2002). Intraperitoneal PYY(3-36) 
increases Fos immunoreactivity in the ARC and downregulates NPY expression in the 
hypothalamus (Halatchev, Ellacott et al. 2004).  Unlike peripheral PYY, centrally 
injected molecule inhibits activity of POMC neurons, which may explain disparate 
feeding effects in animals treated peripherally versus centrally with this peptide 
(Boggiano, Chandler et al. 2005, Ghamari-Langroudi, Colmers et al. 2005). PYY 
produces hypophagia in animals with inactivated MC4 receptor, which suggests that 
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POMC neurons do not mediate the effects of this hormone on appetite and that 
other hypothalamic populations should be considered functionally relevant 
(Halatchev, Ellacott et al. 2004). 
The upper part of the small intestine contains cells that release a recently identified 
anorexigenic hormone, oleoylethanolamide (OEA). The OEA secretory response is 
extremely specific in terms of macronutrient content of food present in the intestine 
as OEA levels rise only upon the ingestion of lipids (Fu, Oveisi et al. 2005, Fu, Astarita 
et al. 2007). OEA’s action is mediated via the nuclear receptor peroxisome 
proliferator-activated receptor alpha (PPAR-alpha) (Fu, Gaetani et al. 2003, Guzman, 
Lo Verme et al. 2004, Yang, Chen et al. 2007). It influences energy homeostasis 
through regulation of lipolysis (Guzman, Lo Verme et al. 2004), as well as through 
triggering central mechanisms that underpin satiety processing. Intraduodenal 
administration of the vector that causes overexpression of N-
acylphosphatidylethanolamine (NAPE)-phospholipase D (PLD), an enzyme catalyzing 
the NAPE à OEA hydrolysis thereby increasing OEA production, decreased calorie 
consumption by elevating feeding latency and postmeal interval (Fu, Kim et al. 2008). 
OEA diminishes appetite in mice and rats (Rodriguez de Fonseca, Navarro et al. 2001, 
Gaetani, Oveisi et al. 2003), and this effect is thought to be mediated via the NTS and 
PVN (Umehara, Fabbri et al. 2016). Importantly, histamine and OT have been 
proposed to be necessary components of hypothalamic circuits responding to OEA 
(Provensi, Coccurello et al. 2014). 
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While the aforementioned gut and adipose hormones (with very few exceptions 
related to, e.g., the aforementioned PYY and concurrent glucose levels) generate 
termination of food intake and – in a long-term – a reduction of body weight,  an 
agonist of the growth hormone secratagogue (GHS) receptor, ghrelin acts as an 
orexigen. Ghrelin is synthesized chiefly by the stomach, although one should note 
that brainstem neurons also express this peptide (Kojima, Hosoda et al. 1999). 
Peripheral and CNS injections of this molecule generate avid consumption whose 
magnitude resembles only that induced by NPY (Bailey, Giles et al. 1999, Wren, Small 
et al. 2001). Not surprisingly, therefore, the GHS receptor is mainly expressed in the 
hypothalamus, particularly in the sites that underpin eating for energy, such as the 
ARC, PVN and VMH, as well as in the dorsovagal complex in the brainstem (Zigman, 
Jones et al. 2006). Administration of ghrelin produces c-Fos expression the ARC, PVN, 
NTS, and DMNV (Hewson and Dickson 2000, Ruter, Kobelt et al. 2003, Takayama, 
Johno et al. 2007) and it induces NPY release from hypothalamic explants (Wren, 
Small et al. 2002). At the CNS level, ghrelin upregulates ARC NPY and AgRP mRNA 
profiles (Kamegai, Tamura et al. 2001) and postnatal deletion of AgRP/NPY cells 
abolishes hyperphagic effects of peripheral ghrelin (Luquet, Phillips et al. 2007). 
Ghrelin inactivation by specific antibodies prevents 2-DG-induced hyperphagia, and 
concomitant changes in activation of LH orexin neurons (Solomon, De Fanti et al. 
2007).  
The overall summary of endocrine and neural communication relevant to the 
hypothalamus and to hypothalamic OT is shown in Figure 1 below. 
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Figure 1. Schematic representation of neural and endocrine communication within 
the peripheral and central pathways that regulate appetite. AP – area postrema; ARC 
– arcuate nucleus; CCK – cholecystokinin; DMNV – dorsal motor nucleus of the vagus; 
GHS-R – growth hormone secretagogue receptor; GLP – glucagon-like peptide; LHA – 
lateral hypothalamus; NTS – nucleus of the solitary tract; OEA – oleoylethanolamide; 
PVN – paraventricular nucleus of the hypothalamus; PPAR-alpha; peroxisome 
proliferator-activated receptor alpha; PYY – peptide YY. 
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1.3. Oxytocin peptide and its receptor as anorexigenic components of central 
pathways regulating appetite  
The peripheral input originating either in the GI tract or in the adipose tissue, needs 
to be integrated at the CNS level in order to trigger central processes responsible for 
adjusting consumption to energy contents of food/energy requirements of the 
organism, to the pleasure of consumption stemming from palatability of the food, 
and to the overall pathophysiological state of the body. Studies strongly suggest that 
hypothalamic OT neurons serve as a crucial element of pathways that integrate the 
diverse routes of feeding-related peripheral information flow into the CNS. 
OT is a neurohormone produced in the CNS, primarily in the paraventricular (PVN) 
and supraoptic (SON) nuclei of the hypothalamus, although other sites of OT 
expression (for example, the brain stem) have also been identified (Choy and Watkins 
1977). Both the PVN and SON contain so-called magnocellular populations of OT 
neurons, whereas the PVN also contains parvocellular OT cells. Magnocellular 
neurons release OT mainly to the general circulation via the posterior portion of the 
pituitary gland, thereby contributing to the peripheral pool of OT. On the other hand, 
parvocellular OT neurons send their projections to a variety of brain areas, such as 
the dorsomedial hypothalamic nucleus, medial preoptic area (MPOA), several 
thalamic nuclei, the dorsal and ventral hippocampus, amygdala, olfactory bulbs, and 
the nucleus of the solitary tract, as well as to the pituitary. As such, centrally derived 
OT affects its receptors scattered throughout the brain as well as in the peripheral 
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tissues (Sawchenko and Swanson 1983, Yamashita, Okuya et al. 1987, Moos and 
Richard 1989, Renaud and Bourque 1991, Morris and Ludwig 2004). 
 
Figure 2. The structure of the oxytocin molecule. 
OT is a nonapeptide (Cys–Tyr–Ile–Gln–Asn–Cys–Pro–Leu–Gly(NH2)) (Fig. 2) with a 
sulphur bridge between the two cysteines. This neuropeptide is evolutionarily 
conserved across species and is thought to have originated ca 500 million years ago 
(Acher, Chauvet et al. 1995). Consequently, virtually all vertebrates carry the genes 
for a variation of the OT-like peptides (the classification depends on the amino acid 
present at the eight position (Table 1.1)) (Gimpl and Fahrenholz 2001). The oxytocin 
receptor (OTr) belongs to the G protein-coupled receptor (GPCR) superfamily, having 
seven transmembrane domains and the alpha-helix (Fig 3). Its activation results in an 
increase of intracellular calcium (Ca2+) and Protein Kinase C (PKC) levels (Fig 3). 
Roughly 80% of OTrs are present in the CNS. The OTr is highly expressed in multiple 
brain regions, for example, in select cortical areas, the olfactory system, the basal 
ganglia, the limbic system, the thalamus, the hypothalamus, the brain stem, and the 
spinal cord, and this broad distribution reflects the plethora of physiological and 
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behavioral o (Rozen, Russo et al. 1995, Breton, Neculcea et al. 1996, Arpin-Bott, 
Waltisperger et al. 1997). OTr mRNA distribution mostly overlaps with OT binding 
sites defined through radiolabeled ligand methodologies (Table 1). 
 
 
Figure 3. The oxytocin receptor is a 7-transmembrane domain G protein-coupled 
receptor. Its elements that interact with the natural ligand molecule are marked with 
the black line (top). The bottom portion of the figure summarizes the cascade of 
cellular responses induced by activation of this receptor. Binding of OT to the OTr 
activates Gα q/11 and then phospholipase C (PLC), which hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and 
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diacylglycerol (DAG). IP3 causes release of Ca2+ from the sarcoplasmic reticulum (SR), 
while DAG activates PKC. Gα q/11 also causes activation of voltage-regulated Ca2+ 
channels and Ca2+ entry into the cell. 
Table 1. Amino acid configuration of oxytocin and oxytocin-like peptides (modified 
from (Gimpl and Fahrenholz 2001)) 
 
Mechanisms regulating food intake ensure that organisms maintain a proper energy 
balance. Physiological systems relevant to feeding continuously facilitate adaptation 
to changes in the internal  Localization of neurons localization at this(understood as 
the biochemical milieu) and external environment. There are two major mechanisms 
defining feeding regulation: homeostatic (feeding for hunger/satiety and protection 
from risks due to excessive stomach distension, osmolality and toxicity) controlled 
mainly by the hypothalamus-brain stem pathways, and non-homeostatic (for 
	 1	 2	 3	 4	 5	 6	 7	 8	 9	
Oxytocin	 Cys	 Tyr	 Ile	 Gln	 Asn	 Cys	 Pro	 Leu	 Gly(NH2)	
Mesotocin	 ∗	 ∗	 ∗	 ∗	 ∗	 ∗	 ∗	 Ile	 ∗	
Isotocin	 ∗	 ∗	 ∗	 Ser	 ∗	 ∗	 ∗	 Ile	 ∗	
Glumitocin	 ∗	 ∗	 ∗	 Ser	 ∗	 ∗	 ∗	 Gln	 ∗	
Valitocin	 ∗	 ∗	 ∗	 ∗	 ∗	 ∗	 ∗	 Val	 ∗	
Aspargtocin	 ∗	 ∗	 ∗	 Asn	 ∗	 ∗	 ∗	 ∗	 ∗	
Asvatocin	 ∗	 ∗	 ∗	 Asn	 ∗	 ∗	 ∗	 Val	 ∗	
Phasvatocin	 ∗	 ∗	 Phe	 Asn	 ∗	 ∗	 ∗	 Val	 ∗	
Cephalotocin	 ∗	 ∗	 Phe	 Arg	 ∗	 ∗	 ∗	 Ile	 ∗	
Annetocin	 ∗	 Phe	 Val	 Arg	 ∗	 ∗	 ∗	 Thr	 ∗	
Vasotocin	 ∗	 ∗	 ∗	 ∗	 ∗	 ∗	 ∗	 Arg	 ∗	
Vasopressin	 ∗	 ∗	 Phe	 ∗	 ∗	 ∗	 ∗	 Arg	 ∗	
Lysipressin	 ∗	 ∗	 Phe	 ∗	 ∗	 ∗	 ∗	 Lys	 ∗	
Phenypressin	 ∗	 Phe	 Phe	 ∗	 ∗	 ∗	 ∗	 Arg	 ∗	
Locupressin	 ∗	 Leu	 ∗	 Thr	 ∗	 ∗	 ∗	 Arg	 ∗	
Arg-conopressin	 ∗	 Ile	 ∗	 Arg	 ∗	 ∗	 ∗	 Arg	 ∗	
Lys-conopressin	 ∗	 Phe	 ∗	 Arg	 ∗	 ∗	 ∗	 Lys	 ∗	
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example, feeding for pleasure) controlled by the reward network of which the two 
main components are the nucleus accumbens (NAcc) and ventral tegmental area 
(VTA) (Benelli, Bertolini et al. 1995, Blevins, Eakin et al. 2003). Importantly, PVN and 
SON OT neurons receive brain stem-derived innervation critical for homeostatic 
control of consumption and they are part of reciprocal circuit with the reward-
related NAcc and VTA (Bagnol, Lu et al. 1999, Arora and Anubhuti 2006, Hayes, 
Skibicka et al. 2008, Hayes, Bradley et al. 2009). Consequently, the OT system 
components have been found in brain areas relevant to homeostatic and non-
homeostatic appetite control: the OT, in the hypothalamus, and the OTr, in the DVC 
and the hypothalamic PVN, SON, VMH and LH.  
Arletti and colleagues were first to report that IP and ICV OT generates hypophagia 
related to energy consumption. They found that OT decreases chow intake, increases 
the latency to start a meal and reduces time spent eating in energy-deprived as well 
as in unrestricted rats. The effects of OT on feeding are reversed by antagonism of 
the OTr. Since that initial report, a number of authors have confirmed the functional 
link between termination of calorie intake and the OT system. For example, OT 
release from the neurohypophysis coincides with cessation of eating behavior 
(Arletti, Benelli et al. 1989). The percentage of activated PVN and SON OT neurons is 
elevated at the end of a meal (Olszewski and Levine 2007). IP, ICV and PVN injections 
of agents that decrease appetite, such as alpha-MSH and GLP-1, produce robust 
activation of OT cells (Olszewski, Wirth et al. 2001, Katsurada, Maejima et al. 2014).  
Interestingly, also peripheral injections of OT decrease feeding (Arletti, Benelli et al. 
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1990). While IP OT decreases appetite, OTr antagonism in the brain stem does not 
completely prevent IP OT-induced hypophagia, but only somewhat dampens it (Ho, 
Anekonda et al. 2014). The effects of peripheral OT might be secondary to processes 
related to energy metabolism and adiposity. In line with that notion, IP OT in mice 
reduces visceral fat mass and improves glucose metabolism (Maejima, Iwasaki et al. 
2011). It elevates the content of N-oleoyl-phosphatidylethanolamine, the OEA 
precursor, in white fat cells (Deblon, Veyrat-Durebex et al. 2011).  
Aside from its involvement in energy intake control, OT protects the organism by 
terminating consumption that can disrupt key homeostatic parameters. For example, 
OT release and neuronal activation occur upon excessive stomach distension when 
large food loads have been consumed (Qin, Feng et al. 2009). This GI 
mechanoreceptor-detected nformation is relayed into the brain by the vagus nerve, 
eventually reaching OT cells via multisynaptic pathways (Berthoud 2008). ICV OT 
reduces gastric motility in a dose-dependent fashion (Dubois-Dauphin, Raggenbass 
et al. 1992). Elevated sodium levels increase OT plasma concentration leading to 
feeding termination (Flanagan, Blackburn et al. 1992). ICV OT decreases salt intake 
(Stricker and Verbalis 1996), whereas genetic deletion of the OTr increases sodium 
consumption (Puryear, Rigatto et al. 2001, Rigatto, Puryear et al. 2003)](Verbalis, 
Mangione et al. 1991)]. Finally, exposure to toxins, such as LiCl and CuSO4, that cause 
GI discomfort and an immediate anorexic response, produces a dramatic increase in 
the number of c-Fospositive OT neurons in the hypothalamus and a surge in 
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circulating OT (Flanagan, Verbalis et al. 1988, McCann, Verbalis et al. 1989, Billig, 
Yates et al. 2001). 
The past several years have brought new discoveries that indicate that brain OT 
controls also a key non-homeostatic aspect of consumption, feeding reward. These 
discoveries define OT as a neuroregulator of complex dietary choice and 
consummatory behavioral processes.  
PVN OT neuronal projections form somatic and axodendritic synapses with 
mesolimbic neurons (Sofroniew 1980, Succu, Sanna et al. 2008). Data from human 
and laboratory animal studies link OT receptor activation with modifications in non-
feeding rewards, from natural rewards, such as social and reproductive behaviors to 
administration of drugs of abuse. For example, cocaine treatment changes OTr 
binding density in the bed nucleus of the stria terminalis in female rats (Johns, Lubin 
et al. 2004, McMurray, Cox et al. 2008). Baracz et al. reported that administration of 
OT in the core of the nucleus accumbens decreases methamphetamine seeking 
(Baracz, Everett et al. 2014). The same group of investigators found also that OT 
attenuates methamphetamine induced conditioned place preference in rats  (Baracz, 
Rourke et al. 2012). In a recently published set of experiments with OTr ligand 
injections in the nucleus accumbens and lentiviral-mediated overexpression of the 
OTr in this site, Bahi showed that OT attenuates ethanol-induced conditioned place 
preference (Bahi 2015). Intracranial infusions of OT in female mice promote the 
development of a conditioned social preference (Kent, Arientyl et al. 2013). Damiano 
et al. showed with fMRI that some single nucleotide polymorphisms in the OTr gene 
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are associated with a differential response of the mesolimbic system during 
anticipation of money rewards in humans (Damiano, Aloi et al. 2014). Neurochemical 
studies have found a relationship between OT and dopamine in perceiving rewards. 
For example, central administration of OT reduced methamphetamine-induced 
dopamine release in the striatum and nucleus accumbens (Qi, Yang et al. 2008), 
decreased glutamate release and increased γ-aminobutyric acid (GABA) in the medial 
prefrontal cortex (Qi, Han et al. 2012). Pioneering studies on feeding reward and OT 
were performed on OT knockout (KO) mice: genetic deletion of OT leads to the 
enhanced initial and sustained intake of palatable sucrose in the KO compared to the 
wild-type (WT) mice (Amico, Vollmer et al. 2005). The effect of the OT KO on sucrose 
consumption occurred in both dark and light phase of the 24-hour cycle and it 
persisted even in animals subjected to periods of repetitive stress (Billings, Spero et 
al. 2006). OT KO and WT mice tested in a progressive ratio operant licking paradigm 
show a similar motivation to consume sucrose (Sclafani, Rinaman et al. 2007). OT KOs 
given a choice between two tastants (water served as a control), exhibit a higher 
preference not only for sucrose, but also for palatable carbohydrate solutions in 
general (e.g., Polycose and cornstarch). A non-caloric non-carbohydrate sweetener, 
saccharin, was also overconsumed by the KOs (Billings, Spero et al. 2006). The 
overconsumption of palatable tastants in OT KO mice does not generalize to fat. Two-
bottle tests in which mice could choose between water and a lipid emulsion showed 
a similar fat preference in KOs and WTs (Sclafani, Rinaman et al. 2007). To further 
examine the issue of preference to fat, Miedlar et al. used a similar paradigm as the 
one used in the initial study on sucrose intake in OT KOs, however, instead of the 
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sugar water, the animals were given Intralipid. OT KO mice drank more Intralipid 
during the first day of having access to the tastants (which may be related to altered 
neophobic or stress-related processing), but on subsequent days they consumed the 
same amount of Intralipid as WTs (Miedlar, Rinaman et al. 2007). The OT KO findings 
are largely in agreement with the results of experiments on laboratory animals 
without genetic modifications. Real-time PCR showed upregulation of OT mRNA in 
the hypothalami of rats eating scheduled, unrestricted, sugar diet compared to 
standard food (Olszewski, Shaw et al. 2009). An increase in OT expression has been 
found in mice given 48-h ad libitum access to a 10% sucrose solution versus animals 
consuming Intralipid (Olszewski, Klockars et al. 2010). Herisson et al. studied 
hypothalamic OT gene expression in mice given short-term access to sucrose, 
cornstarch, or saccharin and found that exposure to carbohydrates but not to 
saccharin elevated OT mRNA above control values; notably, a higher level of 
significance was detected after sucrose intake (Herisson, Brooks et al. 2014). The 
comparison of OT neuronal activity induced by consumption of sucrose or Intralipid 
shows a greater number of Fos positive OT cells in the sucrose group. Injection 
studies using a blood-brain barrier (BBB) penetrating OTr antagonist, L-368,899, in 
choice and no-choice feeding paradigms (Singru, Wittmann et al. 2012), has caused 
increase in carbohydrate intake, but consumption of Intralipid has not been affected 
(Olszewski, Klockars et al. 2010, Herisson, Brooks et al. 2014). When a choice 
between carbohydrates is given, L-368,899 induces preferentially sucrose 
consumption. Mullis et al. have recently reported an important piece of evidence 
linking OT to feeding reward (Mullis, Kay et al. 2013). They implanted rats with a 
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cannula aimed at the ventral tegmental area and found that OT infusion in this site 
decreases deprivation-induced chow intake as well as palatability-driven sucrose 
consumption. These effects are abolished by L-368,899. When L-368,899 or another 
OTr antagonist, (d(CH2)5(1),Tyr(Me)(2),Orn(8))-Oxytocin, were injected alone in the 
ventral tegmental area, they stimulated sugar intake, but they did not change chow 
consumption (Mullis, Kay et al. 2013). This is in agreement with the earlier findings 
showing that when animals are given a choice between sucrose and fat diets, 
systemic administration of an OTr blocker shifts preference towards sugar without 
affecting total energy consumption (Olszewski, Klockars et al. 2010). There have been 
very few studies done in humans. Ott et al (Ott, Finlayson et al. 2013) studied the 
effects of intranasally administered OT on ingestive behavior, with special emphasis 
on rewarding aspects of consumption. OT decrease snack intake (chocolate cookies, 
rice waffles and salt crackers were offered to the subjects) during the snack test 
administered shortly after a full buffet-style breakfast. Total snack intake was 
reduced mainly by restraining by 25% the consumption of high-sugar chocolate 
cookies. 
 Orexigenic opioid receptor ligands (and possibly also other neuromediators of 
feeding for pleasure) diminish meal-end activity of hypothalamic OT neurons. For 
example, butorphanol tartrate at a dose that promotes overeating of sugary foods 
dampens OT PVN neuronal activity in rats that have consumed the amount of high-
sucrose powder diet that is satiating for saline-treated controls (Olszewski and Levine 
2007). Opioid receptor agonists have been shown to decrease OT neuronal activity 
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to noxious stimuli, whereas an antagonist, naloxone, potentiates anorexigenic 
effects of vomiting inducing agents (Flanagan, Verbalis et al. 1988, Olszewski, Shi et 
al. 2000). Mitra et al. showed that daily intake of sucrose in rats reduces c-Fos 
expression in OT neurons after a high-sucrose or low-sucrose meal compared to rats 
receiving daily low-sugar food (Mitra, Gosnell et al. 2010).  
1.4. Devising aims of the project by identifying critical gaps in knowledge: focus 
on contribution of site-specific populations of the OT receptor to appetite control 
The localization of neurons which synthesize a given peptide is certainly a good 
predictor of this peptide’s action or role. One should not, however, neglect of the 
fact that the peptides exerted their actions via intricate networks of receptors that 
are scattered throughout the brain. Therefore, the assessment of the function of 
the signaling molecule should rely to a large extent on the distribution of its 
receptor in discrete central sites.  
This is precisely the case with the pleiotropic neurohormone, OT. Based solely on the 
localization of OT neurons in the hypothalamic PVN and SON, it could be stipulated 
that the maintenance of homeostasis via endocrine control is the primary role of this 
neuropeptide. However, as mentioned in the earlier sections of this chapter, OT 
appears to be involved also in processing a pleasure-related value of consumption. 
Furthermore, oxytocin's effect on food intake seems to be dependent on the social 
status of the animal and that it might also be modified by gender (Olszewski, Klockars 
et al. 2016). Surprisingly, despite this vast array of functions and despite the broad 
expression of the OT receptor throughout the CNS (Table 2), our understanding of 
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which sites relay hypophagic actions of oxytocin is very limited. In fact, only singular 
reports exist that implicate specific reward, hypothalamic and hindbrain elements of 
circuitry in regulating select facets of ingestive behavior. 
Table 2. Feeding-relevant distribution of the OTr in the central nervous system in rats 
(modified from (Gimpl and Fahrenholz 2001)) 
 
Considering the great interest of the scientific community to utilize oxytocin as a 
potential pharmaceutical agent to combat obesity and excessive food intake, it is 
extremely important to define the map of brain areas that are obligatory in 
facilitating OT-induced early termination of consumption. 
The overarching goal of this thesis was to examine whether select circuits expressing 
the OT receptor participate in mediating specific anorexigenic responses to OT. This 
overarching goal was pursued through the following specific aims: 
Brain	Regions																																
mRNA	 OT	binding		
	 Nucleus	accumbens	 +		 +		
	 Bed	nucleus	of	stria	terminalis	(BNST)	 +	+	+		 +	+	+		
	 Central	amygdaloid	nucleus	 +	+	+		 +	+	+		
	 Medial	amygdaloid	nucleus	 +	+		 +		
	 Basolateral	amygdaloid	nucleus	 +	+	+		 +		
	 Paraventricular	thalamic	nucleus	 +	+		 +		
	 Ventromedial	hypothalamic	nucleus		 +	+	+		 +	+		
	 Anterior	medial	preoptic	area	 +	+	+		 -	
	 Supraoptic	nucleus	(SON)	 +	+	+		 (+)	
	 Paraventricular	nucleus	(PVN)	 +	+		 (+)	
	 Ventral	and	dorsal	tegmental	area	 +	+		 -	
	 Nucleus	of	the	solitary	tract	 -	 (+)	
	 Dorsal	motor	nucleus	of	the	vagus	nerve	 +	+	+		 +		
				Medial	preoptic	area			 ++	 +	
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Specific aim 1. To determine whether extreme overeating induced by a powerful 
orexigen, butorphanol tartrate, can be alleviated by pharmacologically stimulating 
the OT receptor in the forebrain versus hindbrain.  
Specific aim 2. To examine whether either of two specific subpopulations of the 
hypothalamic OT receptor, located in the medial preoptic area or the ventromedial 
hypothalamic nucleus, mediates OT-driven hypophagia in energy- and reward-
related facets of ingestive behavior. 
Specific aim 3. To assess whether the OT receptor present in the basolateral and 
central amygdala, sites implicated in emotional processing of food intake, is involved 
in appetite control by OT.  
The studies utilized laboratory rats as an animal model for eating behavior. The 
experimental approaches encompassed intracranial surgeries and drug 
administration, analyses of region-specific expression of genes, brain circuitry-wide 
mapping of immunohistochemically detected immediate-early gene products, and 
examination of feeding behavior parameters related to eating for energy, eating for 
reward, and developing avoidance mechanisms to diets whose consumption 
jeopardizes internal milieu. 
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2.	 Chapter	 Two	 -	 Effects	 of	 lateral	 versus	 fourth	 ventricular	
administration	 of	 oxytocin	 receptor	 ligands	 on	 potent	
orexigenic	effects	of	butorphanol	tartrate	
 
Abstract 
	
Butorphanol tartrate (BT), a mixed mu/kappa/delta opioid receptor agonist, is one 
of the most potent orexigens known to date. Interestingly, BT suppresses meal-end 
activation of neurons synthesizing anorexigenic neuropeptide, oxytocin (OT), which 
suggests that BT promotes hyperphagia by silencing OT-derived satiety signaling.  
Since OT terminates consumption by acting via distinct hindbrain and forebrain 
circuits, I investigated whether stimulation of the OT receptor in the forebrain or 
hindbrain (via lateral (LV) and fourth ventricular (4V) OT injections) leads to 
termination of food intake induced by BT. I established effective doses of BT on 
chow intake in ad libitum-fed and overnight-deprived rats as well as effective doses 
of LV and 4V OT in deprived animals. Then, I determined doses of LV and 4V OT that 
reduce hyperphagia produced by BT in sated and deprived rats. Finally, I assessed 
whether OT’s effects on BT-induced feeding can be suppressed by an OT receptor 
antagonist. 4 mg/kg BT increased intake in ad libitum-fed and overnight deprived 
rats, whereas LV and 4V OT at 1μg caused a decrease in deprived rats. BT-induced 
chow intake in hungry and sated animals was suppressed by a very low, 0.1-μg dose 
of 4V OT, whereas 1μg OT was effective LV. The effect of OT was attenuated by OT 
receptor antagonist, L-368,899. Reduced activity of the OT circuit, especially its 
hindbrain component, is a critical factor in shaping the magnitude of consumption 
in response to the potent BT treatment. 
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Keywords: oxytocin, opioids, food intake, paraventricular nucleus, butorphanol 
 
2.1. Introduction 
Opioid peptide-induced hyperphagia is a well-described phenomenon. All subtypes 
of opioid receptors contribute to increases in feeding. Opioid receptor agonists 
elevate consumption of palatable tastants, promote meal maintenance, and are 
able to stimulate intake of “bland” foods (Gosnell, Levine et al. 1986, Gosnell and 
Levine 2009). Conversely, antagonists reduce eating for pleasure, decrease 
deprivation-induced feeding and support discontinuation of a meal (Bodnar, Glass 
et al. 1995).  
Butorphanol tartrate (BT), a synthetic opioid ligand, is one of the most potent 
orexigens known to date (Morley, Parker et al. 1985, Levine, Grace et al. 1994).  
Yet, our knowledge of mechanisms that mediate its effects on food intake is 
extremely limited. Boggiano et al. (2005) suggested that BT acts chiefly as a kappa 
and mu agonist (Boggiano, Chandler et al. 2005), whereas earlier studies pointed to 
the compound’s affinity for the delta receptor (Chang, Hazum et al. 1981, Lahti, 
Mickelson et al. 1985).  In some paradigms, BT has been shown mixed 
agonist/antagonist-like properties (Craft and McNiel 2003). In feeding studies, BT 
administration has consistently generated robust feeding. Peripheral injections of 
BT elevate intake of standard laboratory chow in non-deprived rats, and the 
magnitude of the orexigenic responses to BT is comparable to those induced by 
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neuropeptide Y (Levine and Morley 1983, Morley, Levine et al. 1983, Jewett, Grace 
et al. 2001, Mitra, Kotz et al. 2012). BT administered centrally, including in the 
paraventricular nucleus of the hypothalamus (PVN), promotes moderate 
hyperphagia, which suggests that peripheral and central mechanisms contribute to 
BT-driven overfeeding.  
It has recently been shown that subcutaneous (SC) administration of BT at an 
orexigenic dose causes a meal-end reduction in the activation of oxytocin (OT) 
neurons in the PVN. Since OT is an anorexigen, that initial finding allowed us to coin 
a hypothesis that BT promotes hyperphagia by suppressing OT-derived satiety 
signaling. In the current set of studies, I further explored this hypothesis by focusing 
on the fact that OT terminates food intake by acting via distinct hindbrain and 
forebrain circuits. Thus, I investigated whether stimulation of the OT receptor in the 
forebrain or hindbrain (via lateral (LV) and fourth ventricular (4V) OT injections) 
leads to termination of food intake induced by BT. I first established the effective 
doses of SC BT on chow intake in ad libitum-fed and overnight-deprived rats as well 
as effective doses of LV and 4V OT in deprived animals. Then, I determined doses of 
LV and 4V OT that attenuate hyperphagia produced by SC BT in sated and deprived 
rats. Finally, I assessed whether OT’s effects on BT-induced feeding can be 
suppressed by an OT receptor antagonist delivered via the same routes. 
2. 2. Materials and Methods 
Animals. Adult male Sprague–Dawley rats (AgResearch, Hamilton, NZ) weighing 
approximately 320g at the beginning of the studies were housed individually in 
Plexiglas cages in a temperature-controlled vivarium (21°C) with LD 12:12 (lights on 
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at 0800). Tap water and standard laboratory chow (Teklad) were available ad 
libitum unless noted otherwise. The University of Waikato animal ethics committee 
had approved the procedures, and they are compliant with the NIH Guide for the 
Care and Use of Laboratory Animals (NIH Publ., no. 80–23, rev. 1996). A different 
set of animals (n=7-9/study) was used for each of the experiments described below. 
Cannula implantation. Animals were anesthetized with the mixture of ketamine 
(100 mg/kg) and xylazine (20 mg/kg) and implanted with a stainless steel cannula 
aimed at the lateral ventricle (LV) or the fourth ventricle (4V). Stereotaxic 
coordinates (Paxinos 1982) for an LV 26-gauge cannula (Plastics One) were 1.5 mm 
lateral to the midline, 1.0 mm posterior to bregma and 3 mm below the surface of 
the skull, whereas a 4V cannula was positioned on the midline 3.2 mm caudal to 
lambda and 7.2 mm below the skull surface. The injector needle extended 1 mm 
beyond the tip of the guide cannula. Dental acrylic was used to secure the cannula 
to two screws inserted in the skull.  
Cannula placement was verified after a 9-12-day recovery period and again, 
following the completion of feeding experiments, via LV injections of 100 ng 
angiotensin II (those rats that drank <6 ml of water within 30 min of the treatment 
were excluded from the study) (Mitra, Klockars et al. 2012) and 4V injections of 30 
pmol bombesin (animals showing more than 25% decrease in food intake were kept 
in the study) (Flynn 1989). 
Drugs and injections. BT was acquired from MSD (NZ), and OT and L-368,899 were 
purchased from Tocris Bioscience (UK), Intracranial injections were performed using 
Hamilton syringes in a volume of 2 μl. Drugs were dissolved in isotonic saline. I 
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employed a repeated measures paradigm, i.e., each animal within a given 
experiment received each dose of the peptide in a counterbalanced manner. 
Hence, each study was divided into sessions spaced 3 days apart. Injections were 
performed between 9:30 and 10:30 in a random fashion.  
Experiment 1: Determining effective orexigenic doses of SC BT in ad libitum-fed 
and overnight-deprived rats. Ad libitum-fed or overnight-deprived rats (in all 
deprivation studies reported here, food was taken away 1-2 h before lights off) 
were injected SC with 0 (saline), 1, 2 and 4 mg/kg b. wt. and pre-weighed chow 
pellets were placed in food hoppers immediately after the drug treatment. Food 
intake was measured 1, 2, 4, 6 and 24 h post-injection. In this and remaining 
experiments, food intake was corrected for spillage. 
Experiment 2: Determining effective anorexigenic doses of LV -and 4V-injected OT 
in overnight-deprived rats. Animals deprived of food overnight were injected in the 
LV or in the 4V with 0 (saline), 0.1, 0.3 or 1 μg OT and chow was returned to 
hoppers just after the drug administration. Food intake was measured 1, 2, 4, and 
24 h post-injection. 
Experiment 3: Effect of LV OT on BT-induced feeding. Ad libitum-fed or overnight-
deprived rats treated SC with an orexigenic dose of BT (4 mg/kg; SC saline-treated 
animals served as controls for BT-induced hyperphagia) were injected 5 minutes 
earlier in the LV or 4V with 0 (saline), 0.1, 0.3 or 1 μg OT.  Pre-weighed chow was 
placed in cages immediately after the second (i.e. SC BT or SC saline) injection. Food 
intake was measured 1, 2, 4, and 24 h post-injection. 
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Experiment 4: Effect of 4V OT on BT-induced feeding. I used the same double-
injection protocol in ad libitum-fed and overnight-deprived rats as described in 
Experiment 3 (section 2.6); however, OT was administered in the 4V at the doses of 
0 (saline), 0.03, 0.1 and 0.3 μg. Food intake was measured 1,2, 4 and 24 h post-
injection. 
Experiment 5: Effect of OTA pretreatment on the ability of OT to affect BT-
induced feeding.  In order to assess whether OT receptor blockade would prevent 
the ability of OT to affect BT-induced feeding, I employed the same protocol as in 
Experiments 3 and 4 (intracranial OT ligand administration followed by SC BT), 
however, 5 minutes prior to injecting animals with effective doses of LV and 4V OT 
(1 and 0.1 μg, respectively), I administered via the same routes 1 (LV) or 0.1 μg (4V) 
of an oxytocin receptor antagonist (OTA), L-368,899. Food was placed in hoppers 
immediately after the SC (BT/vehicle) treatment and consumption was measured 4 
h post-injection. 
Data analysis. Interval intakes were analyzed in all experiments. In Experiments 1 
and 2, analysis was performed with one- factor ANOVA with repeated measures 
and means were compared using Dunnet’s post-hoc test. In experiment 3-4, for a 
two-group comparison (SC BT vs saline) a Student’s t-test was used. To determine 
the effect of OT on BT-dependent feeding, I used one-factor ANOVA with repeated 
measures followed by Dunnet’s post-hoc test with correction for multiple 
comparisons. The effect of OTA on OT-induced changes in feeding in BT-treated 
animals was established using Student’s t-test. Values were considered significantly 
different when P<0.05. Data are presented as a means ± SEM. 
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2.3. Results 
BT increased food intake in both ad libitum-fed and overnight-deprived rats (Fig. 1). 
In ad libitum-fed animals, 2 (P=0.019; F(3,21)= 2.21) and 4 mg (P=0.00043) doses of 
BT were effective during the 1-2 h period, whereas at 2-4 h post-injections, animals 
maintained a significantly higher level of consumption (P=0.00082; F(3,21)=7.81).  
In overnight-deprived rats, only the 4-mg dose of BT produced hyperphagia during 
the 0-1 (P=0.021; F(3,18)=2.64), 1-2 (P=0.004; F(3,18)=5.27) and 2-4 h (P=0.005; 
F(3,18)=4.03) timeframes. There was no effect of BT on 24-h food intake (data not 
shown).  
Overnight-fasted rats treated with 1 μg OT LV or 4V (Fig. 2) showed a reduction in 
food intake during the first hour of re-feeding (P=0.026, F(2,14)=5.02 and P=0.005, 
F(2,14)=8.45, respectively).  
0.1 μg OT administered in the 4V decreased BT-induced chow intake in ad libitum-
fed animals from 2-4 h post-injection (P=0.012; F(4,28)=16.43), whereas the 0.3-μg 
dose was effective during the 1-2 and 2-4 h periods (P=0.020, F(4,28)=5.35 and 
P<0.001, F(4,28)=16.43, respectively). In overnight-deprived BT-treated rats, 0.3 μg 
4V OT reduced consumption at 1-2 h (P=0.002; F(4,24)=9.38) and 2-4 h (P=0.038; 
F(4,24)=4.89) post-injection. A lower dose – 0.1 μg OT – was effective at 1-2 h 
(P=0.028; F(4,24)=9.38). 
Only the 1-nmol dose of LV OT decreased BT-induced food intake in ad libitum-fed 
rats at 1-2 h (P=0.001; F(4,28)=23.34) and 2-4 h post injection (P=0.027; 
F(4,28)=7.02) and in overnight-deprived animals during 0-1 h (P=0.027; 
F(4,24)=7.05), 1-2 h (P=0.034; F(4,24)=7.84), and 2-4 h (P=0.001; F(4,24)=6.41) of 
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re-feeding. LV and 4V OTA reduced the effect of OT on BT-driven food intake in ad 
libitum-fed and fasted rats (Table 4). 
2.4. Discussion 
It has been shown beyond reasonable doubt that opioid peptides increase feeding, 
and that their action via reward-related brain sites, including the nucleus 
accumbens and ventral tegmental area, is of particular importance for the 
orexigenic effects to occur. However, the reward circuit cannot be considered a 
sole player in mechanisms that facilitate voracious food intake induced by opioid 
agonists, such as BT, and a set of more complex neuroendocrine changes is likely 
needed to permit ingestion of large food loads.  This is crucial considering the fact 
that opioids increase consumption beyond actual calorie needs of the animal (thus, 
past the point of satiation), and oftentimes also despite the risks to internal milieu 
brought upon by excessive osmolality, stomach distension or potential toxicity.  
Our previously published data suggest that BT may be silencing satiety signaling 
provided by the OT system: animals injected with SC BT and pair-fed to saline 
controls display a lower level of PVN OT neuronal activation at the end of a meal 
(Kim, Shi et al. 2001). Notably, PVN OT neurons project to a vast variety of forebrain 
and brainstem sites through which they modify consummatory responsiveness, but 
that initial study did not explore which subpopulations of PVN OT cells are affected. 
The current results further substantiate and expand on those early findings, as they 
indicate that BT’s effect on feeding can be attenuated by OT at doses that are 
equivalent to or even much lower than those that reduce energy-driven 
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consumption, but that the hindbrain OT stimulation appears more critical in 
shaping the magnitude of BT-driven hyperphagia. 
The ability of central OT to abolish BT-induced overeating was tested in two BT 
treatment paradigms that differed in energy needs at the onset of the experiment, 
i.e., ad libitum feeding and post-deprivation. I found that BT was effective not only 
in promoting food intake in sated rats, but also in prolonging consumption in 
animals already motivated to eat by overnight fast. Regardless of the paradigm, LV 
and 4V OT suppressed BT-induced feeding. LV OT was effective in BT-injected 
animals at a 1-μg dose, which is minimal to diminish deprivation-induced chow 
intake in BT-untreated rats, as evidenced in our control experiment here as well as 
in previous studies on OT’s effects on appetite after starvation (Arletti, Benelli et al. 
1990, Olson, Drutarosky et al. 1991, Schwartz, Woods et al. 2000). 4V OT also 
reduced appetite in BT-treated rats in both paradigms. Both LV and 4V OT showed a 
similar time course of action in suppressing BT’s hyperphagia: their effect was 
significant during the 1-2 h and 2-4 h period post-injection.  
Importantly, the 0.1-μg dose of 4V OT effective against BT-induced feeding was 10 
times lower than the one needed to decrease deprivation-driven ingestive behavior 
in non-BT animals. This great sensitivity of BT-derived hyperphagia to hindbrain OT 
receptor stimulation strongly suggests that the functional relationship between BT 
and OT in feeding control involves the OT input into the brain stem. While the 
forebrain sites targeted by the OT system, including the dorsomedial nucleus and 
nucleus accumbens, mediate anorexigenic action of OT, the dorsal vagal complex 
(DVC) plays a critical and most comprehensive role in integrating feeding-related 
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peripheral signals (from toxicity to stomach distension and osmotic changes to meal 
size) and OT’s action (Blevins, Eakin et al. 2003). Not surprisingly, therefore, BT  - 
whose effects include promoting overconsumption in a non-hungry state and post-
meal as well as preventing food avoidance despite unpleasant gastrointestinal 
sensation - might depend on the activation of the descending OT pathways into the 
brain stem.  In line with that, it has been shown that orexigenic doses of opioid 
receptor agonists, including BT, simultaneously decrease LiCl-induced activation of 
OT cells in the PVN and unidentified nucleus of the solitary tract neurons 
(Olszewski, Shi et al. 2000). Conversely, naloxone has been found to elevate the 
release of OT induced by administration of cholecystokinin and LiCl and potentiate 
DVC-mediated changes in gastrointestinal motility (Flanagan, Verbalis et al. 1988, 
Leng, Dyball et al. 1992).   
Furthermore, in order to address the question whether the effects of OT injections 
are specific to the OT receptor, I determined that a decrease in BT-induced feeding 
caused by OT can be abolished by a pre-treatment with an OTA delivered via the 
same routes. As OTAs, including L-368,899 used herein, do not increase chow 
intake (Mullis, Kay et al. 2013), it strengthens the notion that the observed effects 
are indeed mediated by the OT receptor. 
2.5. Conclusions 
Overall, our data add to the evidence that BT’s effects on food intake stem, at least 
to some extent, from blockade of tonic feeding-inhibitory pathways. The current 
studies indicate that reduced activity of OT circuit, especially its hindbrain 
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component, is a critical factor in shaping the magnitude of excessive consumption 
in response to BT treatment. 
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2.7.	Figures	and	tables	
	
Figure 1. Effect of SC BT on feeding in rats fed ad libitum (A) and following 
overnight deprivation (B). */**/*** - significantly different from saline-injected 
controls, P<0.05, P<0.01 and P<0.001, respectively.  
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Figure 2. Effect of LV (A) and 4V (B) OT on feeding induced by overnight 
deprivation. */** - significantly different from saline-injected controls, P<0.05 and 
P<0.01, respectively. 
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Figure 3. Effect of LV (A, B) and 4V (C, D) OT on BT-induced feeding in rats fed ad 
libitum (A, C) and following overnight deprivation (B, D).    
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Table 1. Effect of OT receptor antagonist (OTA) pretreatment on the ability of OT to 
suppress 4 mg/kg BT-induced food intake as established in a 4-hour meal in ad 
libitum-fed (left side) and overnight deprived (right side) rats.  
 
Injection Ad libitum-fed rats Injection Overnight 
deprived rats LV SC LV SC 
Saline/saline Saline 3.26 ± 0.72 Saline/saline Saline 11.04 ± 0.71 
Saline/saline BT 7.76 ± 0.46^ Saline/saline BT 16.59 ± 0.54^ 
Saline/OT BT 5.04 ± 0.20* Saline/OT BT 11.45 ± 0.86** 
OTA/OT BT 7.06 ± 0.76 OTA/OT BT 15.89 ÷ 0.64 
4V SC Ad libitum-fed rats 4V SC Overnight 
deprived rats 
Saline/saline Saline 3.5 ± 0.65 Saline/saline Saline 10.54 ± 0.59 
Saline/saline BT 8.3 ± 0.74^ Saline/saline BT 14.99 ± 0.96^ 
Saline/OT BT 5.66 ± 0.45* Saline/OT BT 11.54 ± 0.55** 
OTA/OT BT 7.77 ± 0.62 OTA/OT BT 13.31 ± 0.71 
^ - significantly different from SC saline (P<0.05); */** - significantly different from 
animals treated intracranially with saline/saline and SC with BT (P<0.05 and P<0.01, 
respectively);  	
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3.	Chapter	Three	-	Anorexigenic	potential	of	oxytocin	acting	
directly	in	the	ventromedial	hypothalamic	nucleus	and	medial	
preoptic	area	
	
Abstract 
 
It remains to be elucidated whether oxytocin (OT) reduces various aspects of food 
intake by acting directly at hypothalamic circuits, either via the ventromedial 
hypothalamic nucleus (VMH) or the medial preoptic area (MPOA). Here I provide 
insight into neural mechanisms underlying OT-driven anorexia mediated by the 
hypothalamus by (a) defining whether MPOA or VMH administration of OT affects 
feeding driven by energy needs versus palatability; (b) identifying feeding-related 
brain sites activated by VMH OT injection; (c) measuring VMH OT receptor (OTr) 
mRNA changes in response to hunger and palatability; and (d) examining how VMH 
OT affects episodic sweet solution intake in sated and hungry rats. MPOA had no 
effect on intake of energy-dense standard chow in overnight-deprived rats nor did 
it decrease intake of calorie-dilute palatable solutions that differed in 
macronutrient composition (sucrose- or saccharin-sweetened; or Intralipid-
enriched). On the other hand, VMH OT decreased intake of chow and the effect 
was reversed by the antagonist, though the antagonist alone was not orexigenic. OT 
did not affect intakes of energy-dilute saccharin and sucrose solutions in sated or 
hungry rats. Fos immunoreactivity, a marker of neuronal activation, was elevated in 
the VMH and energy balance-related paraventricular and arcuate nuclei, but not 
reward areas. VMH OTr expression was higher in hungry rats than in sated controls; 
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saccharin intake had no effect. MPOA OT receptor is not involved in OT-driven 
hypophagia mediated by hypothalamic networks. OT acting in the VMH decreases 
intake driven by energy not by palatability, and it stimulates activity of 
hypothalamic sites controlling energy balance.	
Keywords:	oxytocin,	VMH,	reward,	energy	
 
3.1. Introduction	
Arletti and colleagues reported for the first time that intracerebroventricularly (ICV) 
injected oxytocin (OT), a neuropeptide synthesized mainly in the paraventricular 
(PVN) and supraoptic (SON) nuclei and released throughout CNS targets and into 
the general circulation, reduces energy intake (Arletti, Benelli et al. 1989). 
Subsequently, the PVN-brainstem pathway was found to be critical in facilitating 
OT-driven hypophagia (Ho, Anekonda et al. 2014, Olszewski, Klockars et al. 2016). 
Notably, the OT receptor (OTr) is highly expressed also outside the brain stem, 
including in a number of sites that regulate appetite. Among those areas, the 
nucleus accumbens (Acb) and ventral tegmental area (VTA) OTr populations have 
been implicated in feeding control as well (Mullis, Kay et al. 2013, Herisson, Waas 
et al. 2016, Olszewski, Klockars et al. 2016). Importantly, OT appears to be very 
effective in reducing the intake of energy-dense foods (regardless of macronutrient 
composition) and – as shown in several knockout and injection animal model 
experiments – decreasing consumption of sweet solutions (Miedlar, Rinaman et al. 
2007, Mullis, Kay et al. 2013, Herisson, Brooks et al. 2014, Herisson, Waas et al. 
2016). 
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The quest to identify hypothalamic sites that integrate OT’s influence on feeding 
has recently led Noble et al. (Noble, Billington et al. 2014) to note that the 
ventromedial hypothalamic nucleus (VMH) – an area whose malfunctioning leads to 
reduced sympathetic nervous system activity and delayed satiety (Sakaguchi, Arase 
et al. 1988, Tokunaga, Fukushima et al. 1989) - is particularly rich in the OTr and it 
exhibits enhanced neuronal activation after systemic OT treatment (Zhang and Cai 
2011). Consequently, they performed the initial set of experiments showing that OT 
injections in this site reduce energy-driven chow intake at the beginning of the 
night phase and after deprivation, and elevate energy expenditure as well as 
spontaneous physical activity in rats (Noble, Billington et al. 2014).  Unfortunately, 
to date, there has been no additional attempt to further characterize the nature of 
the anorexigenic action of VMH OT.  
On the other hand, a potential involvement of the medial preoptic area (MPOA) in 
mediating OT-driven hypophagia has never been examined. This is particularly 
surprising considering that OT receptors are expressed at a high level in the MPOA 
and that MPOA controls adaptive responses to ambient temperature changes, 
including adjustments in energy expenditure and food intake to compensate for the 
external environmental challenge (Yu, Qualls-Creekmore et al. 2016). 
The current report provides insight into neural mechanisms that underlie VMH OT-
driven anorexia by identifying a network of feeding-related brain sites whose 
activation (determined through c-Fos immunoreactivity) is changed by 
administration of OT in the VMH. I further substantiate the proposed involvement 
of the VMH OTr in feeding control by measuring OTr mRNA changes in this area in 
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response to hunger as well as palatability. I present a series of experiments 
examining the effect of VMH OT on sweet solution intake (episodic in sated and 
hungry animals) and use energy-driven ingestion paradigms (deprivation- and daily 
scheduled intake of standard chow) as control for anorexigenic action of VMH OT. 
Finally, I provide the very first set of data on the ability of OT infused directly in the 
MPOA to affect consumption of standard laboratory chow induced by energy 
deprivation, as well as of calorie-dilute yet highly palatable solutions in non-
deprived rats. 
3.2. Materials and Methods 
Animals and surgeries. Male Sprague–Dawley rats (AgResearch, NZ), aged 9 weeks 
and weighing between 265.1-280.7 g at the beginning of the studies were single-
housed in Plexiglas cages (21°C; 12:12 LD, lights on: 08:00). They had unrestricted 
access to water and standard chow (Teklad) unless noted otherwise. The University 
of Waikato ethics committee had approved the procedures, and they are compliant 
with the NIH Guide for the Care and Use of Laboratory Animals (NIH Publ., no. 80–
23, rev. 1996).  
Animals in injection studies were anesthetized with ketamine-xylazine (100mg/kg + 
20mg/kg) and unilateral 28-gauge stainless-steel guide VMH cannulas (Plastics One, 
Roanoke, VA) were implanted according to the following stereotaxic coordinates: 
+0.5mm lateral, 2.5mm posterior to bregma, and 8.6mm below the skull surface 
(the injector extended 1 mm beyond the tip) (Paxinos 1982). Two stainless steel 
screws inserted in the skull and dental cement were used to secure the cannula. 
Animals were allowed to recover for 8-9 days and afterwards they were subjected 
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to 3 days of handling and sham injections. After completion of the studies, 
histological verification of placement was performed.  
We used two separate main cohorts of cannulated rats: one cohort was used in 
studies on deprivation-induced and scheduled chow intake (Experiments 1, 2), and 
the other, in studies involving palatable liquids and in the c-Fos experiment 
(Experiments 3, 4, 6). The map of correct placements for individual animals 
belonging to these main cohorts is shown in Fig. 1. 
Drugs and injections. OT and L-368,899 (Tocris Bioscience, UK) were dissolved in 
isotonic saline. Injections were done with Hamilton syringes (0.5 μl; 30 s) between 
9:00 and 10:00.  
Experiment 1: Effect of VMH OT and OTr antagonist on deprivation-induced chow 
intake  
Out of 30 rats that were initially equipped with a VMH cannula, 25 had a correct 
placement (Fig. 1). Animals (n=6-7/group) were food-deprived overnight and 
injected in the VMH with either OT (0.3 and 1µg) or saline prior to re-feeding (food 
returned at 10:00). Food intake was measured 1 and 2 h post-injection. After a 
‘wash-out’ period of 4 days, by applying the same deprivation scenario, we 
examined whether VMH L-368,899 (1 and 3μg) by itself changes chow intake during 
re-feeding (saline was used as vehicle; n=6-7/group). 
To assess whether the effect of OT can be blocked with the antagonist, animals 
were double-injected with (a) saline-saline, (b) saline-OT (1µg), (c) L-368,899 (1µg) – 
OT (1µg) (n=6/group). The two injections were spaced 15 min apart. Food was 
		 78	
returned to cages 5-10 min after the second injection and consumption was 
measured 2 h later. 
The validity of the 0.5-µl injection volume is based on diffusion coefficients 
(Nicholson 1985), as well as on previous empirical data, showing ,e.g., the diffusion 
radius of 0.5 μl of 0.5% pontamine blue dye from the PVN to be approximately 0.25 
mm (Wang, Bomberg et al. 2007). It is also the same as the volume used in the 
previous VMH OT study by Noble et al (Noble, Billington et al. 2014) as well in the 
works of other groups that performed targeted intraparenchymal injections (e.g., 
(Fekete, Inoue et al. 2007, Beckman, Shi et al. 2009, Vogel, Wolf et al. 2016)). 
However, to ensure that the injectant volume does not exacerbate the effect of 
VMH OT on deprivation-induced chow intake, in a pilot study, we implanted an 
additional cohort of rats with a VMH cannula. After recovery, these rats were 
subjected to overnight food deprivation and – prior to refeeding – injected with 
only 0.3 µl (instead of 0.5µl) of 1µg OT (n=7) or saline (n=5). We analyzed the data 
with a t-test and found a decrease in 2-h chow consumption from 13.56±1.71g in 
controls to 8.81±0.9g in VMH OT-treated rats (P=0.0119), thus the response 
mirrored the one observed after 0.5µl injections. 
Experiment 2: Effect of VMH OT on scheduled intake of chow 
Following the completion of Experiment 1, animals were accustomed to receiving 
chow only once a day for 2 h (10:00-12:00) over 14 days. VMH injections of OT (0.3 
and 1µg) or saline (n=7/group) were done 10-15 min prior to returning food to 
hoppers and consumption was measured 1 and 2 h later. 
Experiment 3: Effect of VMH OT and OTr antagonist on episodic intake of sweet 
solutions 
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We initially implanted cannulas in 29 rats, however, in one case, the cannula 
became dislodged, and in additional 6 cases, the placement was deemed incorrect 
and the data were discarded.  The animals were used in Experiments 3, 4 and 6 (3-4 
days between experiments were given as a ‘wash-out’). We based the protocol on 
previous OT injection studies (Olszewski, Klockars et al. 2010, Herisson, Brooks et al. 
2014, Herisson, Waas et al. 2016). Animals were accustomed to receiving one of the 
sweet solutions (10% sucrose, 0.1% saccharin) for 2 h/day on 2 days (10:00-12:00) 
prior to the injection experiments to avoid neophobia. First, studies involving 
sucrose (preceded by sucrose solution pre-exposure) were performed. On the 
experimental day, animals were injected with 1μg OT or saline in the VMH. After a 
2-day break, rats were given the 2-h sucrose access again and just prior to it, they 
were injected in the VMH with 1μg L-368,899 or saline (n=11/group).  
Three days without any treatment elapsed. Saccharin pre-exposure was done on 
two consecutive days, followed – 2 days later – by a 2-h experimental session in 
which 1μg OT or saline was injected in the VMH before presentation of 0.1% 
saccharin (n=6/group). In the antagonist study, after a 2-day treatment break, rats 
were given the 2-h saccharin access again and just prior to it, they were injected in 
the VMH with 1μg L-368,899 or saline (n=6/group).  
Palatable solution intake was measured 1 and 2 h post-injection. Chow and water 
were removed during the time of sweet tastant presentation.  
Experiment 4: Effect of VMH OT on intake of a calorie-dilute palatable sucrose 
solution and energy-dense standard chow after a period of overnight food 
deprivation. 
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Prior to injections, animals were accustomed on three different occasions (once a 
week) to receiving 2-h simultaneous access to standard chow and 10% sucrose 
solution (no water) during a re-feeding session after overnight deprivation (from 
10:00 to 12:00). Rats received VMH injections of OT (1µg) or saline just prior to re-
feeding (n=8/group). Consumption was measured after 2 h. 
Feeding data analysis. In experiments involving more than two groups 
(Experiments 1, 2), one-factor ANOVA followed by Fisher’s post-hoc test was used. 
For two-group comparisons (Experiments 3 and 4), a t-test was used. Values were 
considered significantly different when P<0.05. Data are presented as a means ± 
SEM. 
Experiment 5: Changes in VMH OTr expression in rats exposed to food deprivation 
or to a sweet saccharin solution compared to ad libitum chow-fed controls. 
While the control rats had chow and water available ad libitum, the remaining 
groups were either (a) deprived of chow overnight (water remained in the cages) or 
(b) given overnight access to a palatable 0.1% saccharin solution (instead of water; 
chow remained in the cages; n=8/group). The animals were decapitated within the 
first hour after the onset of light, the VMH was dissected and placed in RNAlater 
(Ambion, USA). A previously used standard protocol of sample preparation and 
rtPCR was followed and, for brevity, only the main elements are described (see [5] 
for details). Samples were homogenized in TRIzol (Ambion, USA); RNA was 
extracted with chloroform and precipitated in isopropanol. After centrifuging, the 
pellet was washed, dried, and dissolved in the DNase buffer (NEB, USA). The 
samples were treated with RNase-free DNase I (Merck, Germany) and the absence 
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of genomic DNA was established by PCR of a 5% template. 100ng/μl genomic DNA 
served as a positive control and MilliQ H2O as a negative one. The product was 
analyzed by electrophoresis. 5μg RNA samples were diluted with MilliQ H2O. RNA 
was reverse-transcribed in the master mix (Promega, Australia; 20μl). Samples were 
incubated for 1 h (37°C), followed by PCR to confirm cDNA synthesis. RtPCR 
reactions were performed in duplicates. Sample cDNA template (25ng) was used 
per primer [OTr primer sequences: CGGTGGATCTCGGACTGAAC (fwd) and 
TAGCAGGCGGAGGTCAGAG (rev)]. Expression of three housekeeping genes 
(mRPL19, mCyclo and GAPDH) was used to calculate normalization factors 
(GeNorm, CMG, Belgium). Primer efficiencies were calculated with LinRegPCR 
(HFRC, Netherlands) and Ct values were corrected for differences in primer 
efficiencies. Differences between groups were analyzed with ANOVA, followed by 
Fisher’s test (significant when P<0.05). 
Experiment 6: Effect of VMH OT on Fos IR in feeding-related brain sites 
Rats received a VMH injection of saline or 1μg OT (n=5/group; 4 were excluded due 
to either an incorrect cannula placement (2) or poor staining quality (2)). Food and 
water were then removed. One hour later, animals were perfused with 50 ml saline 
followed by 500 ml 4% paraformaldehyde (PFA). Brains were excised and postfixed 
in PFA. Coronal 60-um vibratome (Leica, Germany) sections were processed for Fos. 
The tissue was treated for 10 min in 3% H2O2/10% methanol in TBS and incubated 
overnight in the goat c-Fos antibody (4°C; 1:2000; Santa Cruz Biotechnology, USA), 
then in the rabbit-anti-goat antibody (1 h; Vector, USA) and finally in avidin/biotin 
(1 h; Vector). Peroxidase was visualized with 0.05% DAB, 0.01% H2O2 and 0.2% 
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nickel sulfate (Sigma, USA). A mixture of 0.25% gelatin and 0.5% Triton X-100 
(Sigma) in TBS was used for incubations. Sections were mounted on slides and the 
number of Fos positive nuclei was counted bilaterally (3-4 sections containing a 
given site per animal), using SCION IMAGE (Scion Corp., USA). Densities of Fos-IR 
nuclei (per mm2) were averaged per rat and group. Differences between the two 
groups were determined with a t-test. 
Experiment 7: Effect of MPOA OT on chow intake after overnight food 
deprivation. Overnight food-deprived rats were injected in the MPOA with 0 
(saline) or 1 μg OT (n=8/group). Pre-weighed chow pellets were placed in food 
hoppers immediately after the drug treatment. Food intake was measured 2 h post-
injection and corrected for spillage.  
Experiment 8: Effect of MPOA OT on episodic intake of palatable solutions. We 
followed a similar protocol as in (Herisson, Brooks et al. 2014). Animals were 
accustomed to having access to a bottle of a 10% sucrose/0.1% saccharin/4.1% 
Intralipid solution for 2 h/day (10:00–12:00; separate experimental sessions for 
each tastant) for 3 days (chow and water were removed for the 2 h). On day 4, just 
before solution presentation, rats were injected in the MPOA with 0 (saline) or 1 μg 
OT (n=6-7/group) and the amount of consumed solution was established 2 h post-
injection. 
3.3. Results 
 Direct VMH OT administration decreased deprivation-induced chow consumption 1 
h (1μg, P=0.0027) and 2 h (0.3μg, P=0.0324; 1μg, P=0.003) post-injection (Fig. 2A). 
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In schedule-fed animals, 1μg VMH OT reduced consumption at the 2-h time point 
(P=0.0014; Fig. 2B).  
While the effect of 1μg VMH OT on hunger-driven feeding (P=0.0027) was reversed 
by a pre-treatment with 1μg OTr antagonist, L-368,899 (Fig. 2C), the antagonist 
itself even at 3μg did not increase chow intake after overnight deprivation (Fig. 2D). 
Daily monitoring of animals did not reveal any effect of OT or the antagonist on 24-
h chow intake (data not shown), similarly to the data presented in the previous OT 
VMH report as well as other site-specific and generalized OT ligand injection studies 
(Herisson, Brooks et al. 2014, Noble, Billington et al. 2014, Herisson, Waas et al. 
2016). 
Consumption of calorie-dilute/non-caloric 10% sucrose and 0.1% saccharin 
remained unchanged even after 1μg VMH OT (Fig. 3A left panel) and 1μg L-368,899 
(Fig. 3A right panel) in energy non-deprived rats. In animals subjected to overnight 
deprivation offered standard chow and 10% sucrose water during re-feeding, 1μg 
VMH OT reduced ingestion of chow (P=0.0105) without affecting sugar solution 
intake (Fig. 3B). RtPCR revealed that VMH OTr expression was elevated in energy-
deprived animals compared to ad libitum-fed controls (P=0.0404), but it was 
unaffected in rats ingesting palatable saccharin (Fig. 3C). 
Finally, direct infusion of OT in the VMH produced an increase in Fos IR in the VMH 
itself (P=0.0221) as well as in the ARC and PVN (P=0.035 and 0.0197, respectively; 
Fig. 4). 
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There was no effect of MPOA OT injected in deprived animals prior to chow 
consumption, nor was MPOA OT effective in reducing intake of palatable solutions 
(Fig. 5). 
3.4. Discussion 
Evidence implicates the VMH in the control of energy intake and expenditure. 
Excessive food intake and obesity are typically observed consequences of VMH 
lesions in laboratory animals, as VMH neurons promote satiety (thereby, directly 
affecting short-term consummatory behavioral responses during a meal) and 
increase energy expenditure by enhancing sympathetic tone leading to negative 
energy balance (Sakaguchi, Arase et al. 1988, Tokunaga, Fukushima et al. 1989). 
Anorexigenic peptides, such as cholecystokinin and leptin, elevate VMH activation 
(Niimi, Sato et al. 1999, Zeeni, Nadkarni et al. 2010). Glucose administration 
increases brain-derived neurotrophic factor (BDNF) expression in the VMH and 
genetic deletion of the BDNF promoter in this site leads to obesity (Unger, Calderon 
et al. 2007). Finally, starvation causes an increase in VMH opioid receptor 
expression (Barnes, Primeaux et al. 2008). In this context, the initial findings of 
Noble et al. showing that VMH OT infusion decreases chow intake and increases 
energy expenditure and spontaneous physical activity, fit in well with the presumed 
role of the VMH in energy balance (Noble, Billington et al. 2014). The current 
studies further substantiate the notion that the VMH OTr plays a crucial role in the 
regulation of feeding for energy, and – notably - they strongly suggest that 
consumption of sweet palatable solutions is not regulated by VMH OT.  
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On the other hand, despite a substantial array of tastants (calorie-dense and –
dilute, as well as non-caloric), I did not observe any change in short-term 
consummatory behavior in MPOA-injected rats. The lack of a relationship between 
MPOA OT and appetite is further underscored by the fact that the dose of OT 
injected in this area is sufficient to reduce all of the tested aspects of feeding upon 
OT administration in the lateral ventricle and the third ventricle. As both lateral and 
third ventricular OT is likely able to access multiple hypothalamic areas, including 
the MPOA, that the activation of the MPOA OT receptor alone does not result in 
changes in appetite, it strongly suggests that this part of the OT hypothalamic 
circuit does not mediate hypophagia. It is in contrast to the MPOA pool of other 
orexigenic and anorexigenic receptors, including galanin-like peptide, orexin A, or 
extrogen (Dagnault and Richard 1997, Patterson, Murphy et al. 2006, Sarihi, Emam 
et al. 2015). 
In our studies, VMH OT, aside from decreasing food intake induced by overnight 
deprivation, was effective in reducing the consumption of chow in a scheduled 
feeding paradigm, in which access to food was restricted to 2 h/day. In that 
scenario, all the calories have to be ingested in the short time frame leading to 
consumption of food in quantities exceeding those in occasional deprivation 
paradigms, as animals are highly motivated by energy needs and entrainment 
serves as an additional factor driving ingestive behavior. It is therefore not 
surprising that, oftentimes, consumption induced by such schedule is not as easily 
modified by pharmacological treatment as in other feeding regimens (Murphy and 
Mercer 2014). Remarkably, VMH OT did reduce the amount of food eaten, with the 
hypophagic effect becoming apparent in the second hour post-injection (of note is 
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the fact that in deprived rats, OT more reliably reduced consumption at 2 h of re-
feeding as well). It underscores the importance of the VMH as a relay site in OT-
driven meal termination, especially in the context of OT promoting early satiety. It 
should be noted that, while we have not measured non-feeding parameters, other 
authors have reported that VMH administration of OT causes a short- lasting 
increase in wheel running activity (30 min) and spontaneous physical activity (1h), 
which indicates that motor impairments do not underlie VMH OT-driven 
hypophagia (Noble, Billington et al. 2014, Narita, Murata et al. 2016). Also, since 
energy expenditure increases briefly in response to VMH OT administration (Noble, 
Billington et al. 2014), therefore, lower energy intake after OT injection cannot be 
interpreted as a compensatory mechanism in energy balance control. The lack of 
effect of VMH OT on the consumption of liquids that contain energy (albeit, dilute), 
further strengthens this argument. 
That the VMH OTr antagonist abolishes the effect of OT on deprivation-induced 
feeding indicates that the anorexigenic action of VMH OT is indeed mediated via 
the OTr. The lack of an increase in chow consumption in the paradigm in which L-
368,899 was administered alone is not surprising: previous studies have shown that 
while the antagonist is very effective in elevating intake of palatable solutions, it 
does not increase energy-dense chow consumption or – in the case of simultaneous 
presentation of two energy-dilute solutions - overall calorie intake (Herisson, Waas 
et al. 2016, Olszewski, Klockars et al. 2016). However, one should remain cautious 
about the possibility that bilateral antagonism of the VMH OT receptor might 
produce hyperphagia. While activating an area unilaterally is certainly enough to 
see the behavioral effects, inhibiting activation may under some circumstances 
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require the contralateral area to be blocked as well, otherwise it will vicariate the 
function. 
Importantly, some authors have pointed to a possible link between the VMH and 
reward-related processing in feeding and non-feeding scenarios. For example, long-
term exposure to cocaine modifies endocannabinoid 1r binding in the VMH and 
direct administration of naloxone in this area blocks conditioned place preference 
induced by paced mating behavior (Garcia-Horsman, Agmo et al. 2008). Figlewicz et 
al. found that VMH Fos levels are higher in rats performing a progressive ration 
operant task for sucrose pellets than in controls (Figlewicz, Bennett-Jay et al. 2011). 
Furthermore, mice chronically maintained on a palatable, high-fat diet show a 
changed VMH dopamine receptor expression pattern (Huang, Yu et al. 2005).  On 
the other hand, mounting evidence suggests that OT is involved in the regulation of 
feeding for reward, especially associated with sweet taste. Rats injected an opioid 
agonist, butorphanol, display a lower number of Fos-IR PVN OT neurons at the end 
of a high-sugar meal than saline controls (Kim, Shi et al. 2001). OT abolishes 
orexigenic action of opioid treatment (Olszewski, Klockars et al. 2016). OT knockout 
mice overconsume saccharin and sucrose solutions, but not fat emulsions (Miedlar, 
Rinaman et al. 2007). Herisson et al. reported that saccharin and sucrose intakes 
are diminished by intra-AcbC OT administration, whereas Mullis and colleagues 
observed a reduction in sugar water consumption after VTA injections of the 
peptide (Mullis, Kay et al. 2013, Herisson, Waas et al. 2016). Peripheral 
administration of a blood-brain barrier penetrant OTr antagonist, L-368,899, 
increase intake of sweet carbohydrate solutions (Herisson, Brooks et al. 2014).   
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Despite the relationship between OT and reward-driven feeding (Olszewski, 
Klockars et al. 2016) and evidence that suggests a link between the VMH and 
reward processing, the data presented herein strongly indicate that OT acting via 
the VMH does not modify intake of palatable sweet solutions. We did not see any 
effect of OT at doses effective at reducing deprivation- and schedule-induced 
energy-dense chow intake on the episodic consumption of non-caloric saccharin 
and calorie-dilute 10% sucrose solution in sated rats (and, as mentioned before, the 
antagonist did not elevate intake of the palatable tastants). Introducing the context 
of energy deprivation prior to giving animals simultaneous access to energy-dense 
standard chow and palatable (though low-energy) sugar water generated vigorous 
consumption of both tastants. However, also in this case, VMH OT diminished the 
intake of chow and the total number of calories, but it did not decrease appetite for 
sucrose.  
The feeding data are in agreement with our Fos and rtPCR findings. Direct 
administration of OT in the VMH leads to an increase in neuronal activity of the 
VMH itself and it engages a wider network of sites controlling mainly hunger-satiety 
responses, including the hypothalamic PVN and ARC. Though the change in Fos-IR 
might be associated with indirect and direct VMH-derived downstream input, the 
activation of the PVN and ARC is aligned with previously proposed functional 
pathways related to feeding control. For example, Sternson et al. found that ARC 
proopiomelanocortin neurons receive strong excitatory input from the medial VMH 
and its strength is diminished by hunger (Sternson, Shepherd et al. 2005). Canteras 
and colleagues reported that all subdivisions of the VMH supply dense projections 
to the PVN and it has been suggested that BDNF-PVN corticotropin releasing 
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hormone pathway might be essential in satiety responsiveness (Canteras, Simerly 
et al. 1994). Finally, the rtPCR data showing upregulation of the OTr mRNA in the 
VMH of fasted rats indicate that with the diminished OT tone due to the lack of 
consummatory activity, the VMH OTr expression increases; whereas the lack of 
change after exposure to a palatable saccharin solution suggests that the VMH OTr 
population is not affected by fluctuations in OT tone in response to feeding reward. 
Overall, our results define the VMH with the OTr as a circuit that is dynamically 
regulated by energy status in a manner consistent with the known role of the VMH 
and OT in satiety control. 
3.5. Conclusions 
Overall, our data add to the evidence that OTr in the VMH is involved in the 
termination of consumption driven by energy needs not by reward derived from 
consuming palatable yet calorie-dilute solutions. OT action at the VMH activates 
hypothalamic sites involved mainly in energy balance control, and it is not 
associated with an altered Fos IR in sites directly linked with pleasure-driven 
consumption. MPOA OT receptor is unlikely to be involved in the regulation of food 
intake. 
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3.7.	Figures	
	
Figure 1. A photomicrohraph (A) and schematic representation (B) of 
intraparenchymal VMH injection sites in animals used in Experiments 1, 2 (left side 
of the panel) and in the cohort used in Experiments 3, 4, and 6 (right side of the 
panel). 
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Figure 2. VMH OT and standard chow intake. Effect of (A) VMH OT on deprivation-
induced chow intake (n=6-7/group), (B) VMH OT on scheduled chow intake 
(n=7/group), (C) VMH OTr antagonist, L-368,899, on VMH OT-driven reduction in 
deprivation-induced chow intake at 2 h of consumption (n=6/group), and (D) VMH 
L-368,899 on chow consumption after deprivation (n=6-7/group). */** - different 
from saline-injected controls, P<0.05 and P<0.01, respectively.  
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Figure 3. Sweet tastant intake and VMH OTr. Effect of direct VMH injection of (A) 
OT or OTr antagonist, L-368,899, on episodic 2-h intake of 10% sucrose 
(n=11/group) and 0.1% saccharin solution (n=6/group) in non-deprived rats (chow 
taken away during the 2-h sweet solution presentation),  (B) OT on 2-hour intake of 
simultaneously presented standard chow and palatable 10% sucrose solution after 
overnight deprivation (n=8/group). (C) Effect of overnight energy deprivation and 
saccharin exposure (instead of water) vs ad libitum chow-fed controls on relative 
expression of VMH OTr mRNA (n=8/group). * - significantly different, P<0.05. 
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Figure 4. Effect of VMH OT (1 ug) vs saline on Fos immunoreactivity in feeding-
related brain sites. Photomicrographs depict the ventromedial (VMH: top – cannula 
tract shown: ct), arcuate (ARC, middle) and paraventricular (PVN) nuclei. * - 
significantly different, P<0.05. MPOA, medial preoptic area; SON, supraoptic n.; LH, 
lateral hypothalamus; AcbC/S, n. accumbens core/shell; VTA, ventral tegmental 
area; CeA, central n. of the amygdala; BLA, basolateral amygdala; NTS, n. of the 
solitary tract; DMNV, dorsal motor n. of the vagus. Scale bar: 0.6mm; n=5/group. 
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Figure 5. MPOA OT and food consumption. Effect of direct MPOA injection of 1 ug 
OT on (A) deprivation-induced chow intake 2 h post-administration (n=8/group); (B) 
episodic 2-h intake of 10% sucrose (n=6/group), (C) 0.1% saccharin solution 
(n=7/group) and (D) 4.1% Intralipid (n=7/group) in non-deprived rats (chow taken 
away during the 2-h solution presentation). 
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4.	 Chapter	 Four	 -	 Basolateral	 and	 central-amygdalar	 oxytocin	
moderately	suppresses	food	intake	
	
Abstract 
Central oxytocin (OT) decreases meal size and reduces intake of palatable sweet 
solutions. It remains largely unclear as to which brain sites mediate OT’s effect on 
palatability versus energy or the combination of those aspects of consumption. In 
the project described in this chapter of the thesis, I expanded the search for sites 
that mediate anorexigenic properties of OT by focusing on two subdivisions of the 
amygdala, its central (CNA) and basolateral (BLA) nuclei. I injected OT directly in the 
BLA or CNA in rats and assessed intake of standard chow induced by energy 
deprivation and intake of sweet solutions in non-deprived animals. I examined 
whether these effects are reversible by OT receptor (OTr) antagonism and whether 
BLA or CNA OT induces taste aversion. I also determined the effect of energy 
deprivation and exposure to sweet saccharin on BLA and CNA expression of OTr 
mRNA. BLA OT at 0.3 μg and CNA OT at 1 μg reduced standard chow intake after 
deprivation by ~25%. Only BLA OT was effective at suppressing consumption of 
sucrose and saccharin solutions.  The anorexigenic effects of BLA and CNA OT were 
attenuated by OTr antagonist, L-368,899, pretreatment. OT at anorexigenic doses 
did not promote acquisition of taste aversion. BLA OTr mRNA expression was 
affected by exposure to palatable saccharin, whereas that of CNA OTr, by energy 
deprivation. OT in the amygdala moderately decreases food intake. The functional 
relationship between amygdalar OT and energy intake versus palatability-driven 
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intake depends on the discrete localization of the OTr within this complex 
structure.   
Keywords: oxytocin; satiety; reward; sugar; appetite 
4.1. Introduction 
The early discovery by Arletti et al. showing a decrease in food consumption after 
intracerebroventricular (ICV) administration of oxytocin (OT) in rats (Arletti, Benelli 
et al. 1990), sparked interest in defining mechanisms that underlie OT-driven 
hypophagia. The presence of reciprocal hypothalamic OT – brainstem pathways, 
particularly those incorporating dorsal vagal complex, served as an anatomical basis 
linking OT with the regulation of meal size as a means to protect internal milieu 
(Blevins, Eakin et al. 2003). OT release is associated with stomach distension, 
elevated plasma osmolality and toxicity-derived gastrointestinal (GI) discomfort 
(Renaud, Tang et al. 1987 , Olson, Drutarosky et al. 1991, Olszewski, Waas et al. 
2013). OT neuronal activity coincides with an end of a meal and occurs upon 
administration of GI and central mediators of satiety, including cholecystokinin 
(CCK) and glucagon-like peptide (Renaud, Tang et al. 1987, Bojanowska and 
Stempniak 2001). Direct hindbrain and hypothalamic infusions of OT reduce energy 
intake (Arletti, Benelli et al. 1990, Klockars, Waas et al. 2017).    
More recent studies indicate that central OT regulates another key aspect of 
appetite, eating for palatability. The OT receptor (OTr) is expressed in the reward 
circuit and changes in OTr levels have been reported in rats drinking sweet 
solutions (Herisson, Waas et al. 2016). A blood-brain barrier-penetrant OTr 
antagonist, L-368,899, while ineffective in altering consumption of standard chow, 
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stimulates sugar water intake in non-choice and choice scenarios (Olszewski, 
Klockars et al. 2010). In wild-type mice, it promotes consumption of sweet calorie-
dilute solutions. OT knockout (KO) mice show greater preference for sucrose and 
saccharin (Billings, Spero et al. 2006, Miedlar, Rinaman et al. 2007, Herisson, Brooks 
et al. 2014).  
It remains largely unclear as to which brain sites mediate OT’s effect on palatability 
versus energy (or the combination of those). Thus far, microinjection studies have 
shown that OT administered in two key components of the reward system, the 
ventral tegmental area (VTA) and nucleus accumbens (Acb), is highly effective in 
decreasing episodic consumption of calorie-dilute and non-caloric palatable 
solutions sweetened with sugar and saccharin, even in the absence of hunger 
(Mullis, Kay et al. 2013, Herisson, Waas et al. 2016). Conversely, hypothalamic OT 
reduces only intake of energy-dense tastants regardless of their palatability 
(Klockars, Waas et al. 2017). 
In the current investigation, I expand the search for sites that mediate anorexigenic 
properties of OT by focusing on two subdivisions of the amygdala, its central (CNA) 
and basolateral (BLA) nuclei. The amygdala expresses the OTr and its activity in 
response to food cues is exacerbated by energy needs (Sun, Kroemer et al. 2015). I 
infused OT directly in these areas in rats and examined the effect on intake of 
standard chow induced by energy deprivation and on the intake of palatable sweet 
solutions (or water) in energy non-deprived animals. I assessed whether the 
anorexigenic properties of BLA and CNA OT stem from aversion and whether they 
can be reversed by antagonism of the OTr. Finally, I determined the effect of energy 
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deprivation as well as of exposure to palatable sweet saccharin on the expression of 
the OTr in the BLA and CNA. 
4.2. Materials and Methods 
Animals. Adult male Sprague–Dawley rats (AgResearch, Hamilton, NZ) weighing 
320±11 g at the beginning of the studies were single-housed in Plexiglas cages 
(21°C; LD 12:12, lights on at 07:00). Rats had unrestricted access to water and 
standard chow (Teklad) unless stated otherwise. The UoW ethics committee had 
approved the procedures, and they are compliant with the NIH Guide for the Care 
and Use of Laboratory Animals (NIH Publ., no. 80–23, rev. 1996).  
Surgeries. Animals were anesthetized with the ketamine–xylazine mixture (100 
mg/kg + 20 mg/kg) and stereotaxically equipped with a cannula (Plastics One) 
aimed at the BLA or CNA. The cannula was secured with dental acrylic to two 
screws inserted in the skull. The following placement coordinates (Paxinos 1982) 
were used: (a) BLA: 5.1 mm lateral to the midline,  2.4 mm posterior to bregma and  
7.5 mm below the surface of the skull; (b) CNA: 4.3 mm lateral to the midline, 2.64 
mm posterior to bregma and 7.0 mm below the skull surface. The injector extended 
1 mm beyond the tip of the guide cannula. Rats were allowed to recover for 9 days. 
Placement was verified histologically after completion of the studies. 
Drugs and injections. OT and L-368,899 were purchased from Tocris (UK). 
Intracranial injections were performed using Hamilton syringes in a volume of 0.2 
μl. OT was delivered within the range previously reported to affect appetite with 
site-specific administration (0.03 μg = 29.8 pmol; 0.1 μg = 99.3 pmol; 0.3 μg = 297.9 
pmol and 1 μg = 993.1 pmol) (Mullis, Kay et al. 2013, Herisson, Waas et al. 2016, 
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Klockars, Waas et al. 2017). Drugs were dissolved in isotonic saline. In Experiment 1, 
a repeated measures paradigm was used, in which each animal received each dose 
of the drug in a counterbalanced manner. Hence, this study was divided into four 
sessions spaced 3 days apart. The remaining studies included a single experimental 
session. 
Experiment 1: Effect of BLA and CNA OT on chow intake after overnight food 
deprivation. Overnight food-deprived rats were injected in the BLA (n=11 – 
repeated measures) or CNA with 0 (saline), 0.1, 0.3 or 1 μg OT (n=10 – repeated 
measures). Pre-weighed chow pellets were placed in food hoppers immediately 
after the drug treatment. Food intake was measured 2, 4 and 24 h post-injection 
and corrected for spillage.  
Experiment 2: Effect of BLA and CNA OT on episodic intake of palatable sweet 
solutions. We followed a similar protocol as in (Herisson, Brooks et al. 2014). 
Animals were accustomed to having access to a bottle of a 10% sucrose solution for 
2 h/day (10:00–12:00) for 3 days (chow and water were removed for the 2 h). On 
day 4, just before sucrose presentation, rats were injected (a) in the BLA with 0 
(saline), 0.03, 0.1 or 0.3 μg OT (n=8-10/group) or (b) in the CNA with 0 or 1 μg OT 
(n=8/group) and the amount of consumed solution was established 2 h post-
injection. The same approach was employed to study the effect of OT on 0.1% 
saccharin intake, however, in the case of BLA injections, 0, 0.1, 0.3, or 1 μg OT was 
used (n=8-9/group), whereas CNA animals were treated with 0 or 1 μg OT 
(n=8/group). 
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Experiment 3: Effect of BLA and CNA OT on deprivation-induced water intake. 
Rats were water-deprived overnight and injected in the BLA or CNA with either 0 
(saline) or 1 µg OT (BLA, n=8-9/group; CNA, n=7/group) prior to regaining access to 
water. At 10:30, water bottles were returned to the cages and intake was measured 
2 h post-injection. Chow was removed from hoppers during the time of the drinking 
test. 
Experiment 4: Effect of OT antagonist pretreatment on hypophagic properties of 
BLA and CNA OT. We used those paradigms in which OT was found to produce 
hypophagia (for BLA: deprivation-induced chow intake and intake of sweet 
solutions; for CNA: deprivation-induced chow intake). Just prior to gaining access to 
either chow (deprivation paradigm), a sucrose or saccharin solution (sweet 
solutions paradigm), the animals received two intra-amygdalar (BLA or CNA) 
injections spaced 10 min apart: (a) saline followed by saline; (b) saline followed 1μg 
OT (effective OT dose); (c) 1 μl L-368,899 followed by 1μg OT; (d) 1μl L-368,899 
followed by saline (n=9/group in BLA and CNA injections). Intake of chow was 
measured at 4 h after the second injection and of palatable solutions at 2 h. 
Experiment 5: Effect of BLA and CNA OT on the acquisition of a conditioned taste 
aversion (CTA). Animals were accustomed to receiving water for 2 h (10:00–12:00) 
per day for 3 days. Chow was removed for the 2 h of water presentation. On day 4, 
rats were given a novel cherry KoolAid solution (Kraft Foods; prepared as per 
manufacturer’s recommendation) instead of water for 2 h. Afterwards they 
received a BLA or CNA injection of saline or 1μg OT (an effective anorexigenic dose 
based on chow experiments; n=5/group). Rats treated with IP 6 mEq LiCl (versus IP 
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saline) served as a positive control for a CTA (n=5/group). On day 5, a two-bottle 
preference test between KoolAid and water was used to assess acquisition of a CTA 
to KoolAid. Bottles were weighed and percentages of KoolAid intake (out of 
cumulative, i.e. KoolAid plus water, intake) were calculated. 
Ingestive behavior data analysis. Experiment 1 data were analyzed with repeated 
measures ANOVA followed by Dunnet’s post-hoc test with correction for multiple 
comparisons. Data from the remaining studies utilizing single injections were 
processed with a Student’s t-test (two-group comparisons) or one-way ANOVA 
followed by Dunnet’s test (multiple-group comparisons). Values are shown as 
means ± SEM and they were deemed significantly different when p≤0.05. 
Experiment 6: Relative expression of OTr mRNA in the BLA and CNA in animals 
subjected to food deprivation or exposed to palatable saccharin. In order to assess 
the effect of sweet palatable saccharin solution exposure on BLA and CNA OTr 
mRNA levels, rats were given chow and 0.1% saccharin (instead of water) for 48h, 
whereas assessing the effect of food deprivation was done in animals that did not 
have access to standard chow (water available at all times) for 24 h prior to 
decapitation. Rats maintained on chow and water ad libitum served as controls. The 
rats (n=6-8/group) were decapitated (9:00-10:00), coronal brain slices were made 
using the matrix, the BLA and CNA were excised and placed in RNAlater (Ambion) at 
21°C for 2 h and then at 4°C overnight. For brevity reasons, only the main steps of 
the standard protocol are described below (for details, see (Olszewski, Klockars et 
al. 2010)). Samples were homogenized in TRIzol (Ambion). Extractions were done 
with chloroform, and isopropanol was used to precipitate RNA. Samples were 
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centrifuged, pellets rinsed, dried, and dissolved in the DNase buffer (NEB). The 
samples were treated with RNase-free DNase I (Merck) at 37°C for 1 h. The absence 
of genomic DNA was determined by PCR of 5% template in the PCR mix [MgCl2-free 
buffer, 50mM MgCl2, Tween, 20mM dNTP, fwd. and rev. primers, Taq polymerase, 
and MQ H2O; 10 μl volume]. 0.5μl 100ng/μl genomic DNA was a positive control, 
whereas 0.5μl MilliQ H2O served as a negative one. The product was analyzed with 
electrophoresis. For cDNA synthesis, 5-μg RNA samples (concentration determined 
with Nanodrop) were diluted with MQ H2O to 12 μl. RNA was reverse-transcribed in 
Master Mix (Promega). Samples were incubated for 1 h at 37°C, followed by PCR to 
establish cDNA synthesis. Reactions were performed in duplicates; negative 
controls were included. 25 ng of sample cDNA template was used per primer (OTr 
primers: ttcttctgctgctctgctcgt (fwd) and tcatgctgaagatggctgaga (rev)). Each rtPCR 
contained 2μl 10×MgCl2-free buffer, 0.2 μl 20mM dNTP, 1.6 μl 50 mM MgCl2, 
forward and reverse primers (0.05 μl; 100 pmol/μl), 1 μl DMSO, 0.5 μl Sybr Green 
(1:50000), 0.08 μl Taq polymerase, and 9.52 μl MQ H2O. Amplification consisted of 
denaturation (95°C, 3min), and 40 cycles of denaturing (95°C, 20s), annealing (30s), 
and elongation (72°C, 30s). Normalization factors were established by analyzing 
expression of three HKGs: GAPDH (fwd. acatgccgcctggagaaacct; rev. 
gcccaggatgccctttagtgg), cyclophilin (fwd. gagcgttttgggtccaggaat; rev. 
aatgcccgcaagtcaaagaaa), and ribosomal protein 19 (fwd. tcgccaatgccaactctcgtc; rev. 
agcccgggaatggacagtcac) (GeNorm). Primer efficiencies were calculated with 
LinRegPCR, and Ct values were corrected for differences in efficiencies. Grubb's test 
was used to calculate average PCR efficiencies for primer pairs. Differences in OTr 
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expression between groups were analyzed with ANOVA followed by Bonferroni’s 
test (significant when p ≤ 0.05). 
4.3. Results 
OT decreased deprivation-induced chow intake in BLA- and CNA-treated animals 
(Fig.1C,D). BLA OT was effective at 0.3 and 1 μg after 2 h (F(3, 30)=5.575; p=0.0012, 
and p=0.022, respectively) and 4 h post-injection (F(3, 30)=4.73; p=0.011, and 
p=0.046, respectively). CNA OT reduced chow consumption only at the 1 μg dose at 
2 and 4 h (F(3, 27)=5.41, p=0.0042; and F(3, 27)=3.787, p=0.015, respectively), 
although there was a trend (p=0.0559) with 0.3 μg at 4 h. We did not observe any 
differences after 24 h (data not shown). 
CNA OT was ineffective at diminishing sugar or saccharin solution consumption, 
however, BLA OT decreased episodic intake of the sweet fluids (Fig 1E,F). Intake of 
sucrose was affected by 0.1 and 0.3 μg OT (F(3, 32)=4.985; p=0.0478, and p=0.0462, 
respectively), whereas 1 μg was needed to reduce the amount of ingested 
saccharin (F(3, 21)=5.271, p=0.0076). Neither BLA nor CNA OT changed water intake 
in thirsty rats (Fig. 1G,H).  
In the antagonist studies, 1 μg OT reduced intake of chow (BLA, F(3, 32)=2.514, 
p=0.0323; CNA, F(3, 32)=3.13, p=0.0484) at 4 h in re-fed rats as well as - in BLA 
injections - intake of sugar (F(3, 32)=2.446, p=0.033) and saccharin (F(3, 32)=4.443, 
p=0.0219). Rats pretreated with the antagonist, L-368,899 (1 μg) prior to OT 
administration ingested similar amounts of either chow or sweet solutions as 
relevant controls (Fig. 2 A, B). Unlike IP LiCl used as a positive control for a CTA 
(p<0.0001), neither BLA nor CNA OT induced a CTA to a KoolAid solution (Fig. 2 C).  
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Finally, saccharin consuming animals showed a marked decrease in BLA OTr mRNA 
levels (F(2, 18)=5.594; p=0.007), whereas food deprivation upregulated CNA OTr 
expression (F(2, 19)=7.614; p=0.0443). 
4.4. Discussion 
While obtaining energy is the main reason that underlies food intake, energy 
balance is not a sole factor that affects consumption. Additional controls shaping 
the magnitude of ingestive behavior, such as emotional processing or memory, 
have evolved in order to maximize consumption of physiologically beneficial foods 
and to adjust food intake to a dynamic state of the organism.  
The amygdala is proposed as a key structure linking emotional responsiveness and 
hunger-driven eating behavior. Activity in the amygdala is elevated in people 
subjected to visual food cues, and it further increases by fasting (Sun, Kroemer et 
al. 2015). Anatomically separable into two groups, one that includes the BLA whose 
internal circuitry is more cortical, and another that is more striatal, involving the 
CNA, the amygdala is synaptically interconnected with the hypothalamus, striatum, 
and limbic system. (Swanson 2003). Furthermore, it expresses a plethora of 
receptors known to mediate hypo- and hyperphagia, including those for opioids 
and ghrelin (Beckman, Shi et al. 2009, Alvarez-Crespo, Skibicka et al. 2012). Despite 
the fact that amygdala neurons belong to a feeding-related circuit, our 
understanding of their precise involvement in food intake is limited. Here, we show 
for the first time that OT acting in the BLA and CNA, moderately suppresses 
appetite. The functional relationship between amygdalar OT and feeding depends 
on the discrete localization of the OTr within this complex structure.   
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Both the BLA and CNA injections of OT caused a transient ~25% decrease in 
deprivation-induced intake of energy-dense ‘bland’ chow. That neither BLA nor CNA 
OT induced a CTA indicates that the anorexigenic properties of intra-amygdalar OT 
do not stem from malaise. This short-lived decrease in hunger-driven consumption 
was similar in magnitude to what had been previously reported for OT 
administered in the reward-related Acb, and somewhat less pronounced than 
either after ICV (which leads to simultaneous targeting of the OTr in multiple sites) 
or after energy balance-linked ventromedial hypothalamic nucleus (VMH) injections 
(Arletti, Benelli et al. 1990, Herisson, Waas et al. 2016, Klockars, Waas et al. 2017). 
The doses used here have been typically found effective in intraparenchymal OT 
infusion experiments published to date, though our understanding of how these 
doses relate to physiological levels of the peptide is limited (Mullis, Kay et al. 2013 , 
Herisson, Waas et al. 2016). Importantly, hypophagia caused by BLA and CNA OT 
was abolished by a pre-treatment with an antagonist delivered via the same routes. 
It strengthens the notion that the observed effects of BLA and CNA OT on 
deprivation-induced feeding are indeed mediated by the OTr and it implicates intra-
amygdalar OT in the regulation of consummatory responses to energy needs. This 
outcome is in concert with the proposed function of OT in ‘homeostatic’ control of 
meal size. It is also in agreement with the growing body of evidence showing that 
targeting with selective ligands those subsets of amygdala neurons that express 
receptors for orexigenic and anorexigenic peptides (e.g., galanin, ghrelin and NPY) 
produces changes in the intake of food irrespective of palatability (e.g., see 
(Beckman, Shi et al. 2009, Alvarez-Crespo, Skibicka et al. 2012)). Notably, the 
amygdala (especially, CNA) has been also linked to glucose metabolism and 
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adiposity, which further underscores its sensitivity to energy states of the organism 
(Mendes, Castro et al. 2017).  
Even if one considered the amygdala to be involved primarily in emotional aspects 
of feeding control, the fact that amygdalar OT affects the intake of standard chow 
in hungry animals is not surprising as reward and energy needs are intertwined. In 
line with that, changes in hunger-satiety responses to ‘bland’ diets in deprived 
animals have been shown upon manipulating neural circuits primarily recognized 
for reward processing (as there is a rewarding component of replenishing calories). 
It should be noted, though, that the results of our palatable sweet tastant studies 
suggest that a palatability-OT relationship exists only in the context of BLA 
injections. We found that intakes of a calorie-dilute sucrose solution and non-
caloric saccharin are reduced by BLA OT (0.1 and 1 µg were effective), but not by 
even the highest dose of CNA OT. The intra-amygdalar OT does not affect water 
intake, and thus the effects of BLA OT on drinking sweet solutions are unrelated to 
thirst. These data write well into the existing literature indicating the role of BLA as 
a neural integrator of reward value (Wassum and Izquierdo 2015). BLA is involved in 
encoding emotional events with reference to their particular sensory-specific 
features (Balleine and Killcross 2006). Activation of BLA cells after an unconditioned 
stimulus is necessary for the expression of both an innate and a conditioned 
response (Gore, Schwartz et al. 2015). Intuitively, therefore, exposure to rewarding 
sugar has been found to attenuate BLA output and increase expression of genes 
driving plasticity (Packard, Di et al. 2017).  
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Importantly, parallel to the disparate effects of CNA vs BLA OT on ingestion of 
sweet solutions, the CNA and BLA have been proposed to play distinct (albeit, yet 
not fully understood) roles in reward processing. For example, BLA but not CNA 
lesions interfere with conditioning and reinforcer devaluation effects (Hatfield, Han 
et al. 1996). On the other hand, inactivation of the CNA but not BLA disrupts 
learning in response to over-expectation of reward (Haney, Calu et al. 2010). 
Furthermore, though the BLA and CNA receive gustatory input, this overlap is only 
partial (Swanson 2003). Hence, in the context of appetite regulation, it is quite 
plausible that while BLA OT affects the portion of feeding driven by reward, CNA OT 
plays a more profound role in the ‘homeostatic’ regulation of a meal size. This 
notion is supported by the outcome of the OTr gene expression study. In the CNA, 
deprivation-induced changes in the OTr mRNA levels (and, simultaneously, no 
effect of saccharin consumption) mirror those observed in the VMH (VMH OT does 
not affect sucrose or saccharin intake). Conversely, OTr expression changes in the 
BLA after saccharin exposure are similar to what has been reported for the Acb, a 
key reward site.  
We conclude that OT acting in the BLA and CNA decreases deprivation-induced 
intake of chow and the anorexigenic properties of BLA OT extend onto sweet 
palatable solutions. Thus, the functional relationship between amygdalar OT and 
appetite depends on the discrete localization of the OTr within this complex 
structure.    
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4.6.	Figures	
	
Figure 1. Effect of BLA (left panel; cannula placement shown in A) and CNA (right 
panel; cannula placement shown in B) administration of OT on standard chow 
intake induced by overnight deprivation (C, D), on consumption of palatable sweet 
10% sucrose or 0.1% saccharin solutions in non-deprived animals (E, F), and on 
intake of water in thirsty rats (G, H). OT doses shown in µg (0 µg indicates saline 
control). */** - significantly different from saline-injected controls, P<0.05 and 
P<0.01, respectively. # - p=0.0559. CT, cannula tract; opt, optic tract. 
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Figure 2. Effect of site-specific OTr blockade with 1 µg OTr antagonist, L-369,899 
(X), on (A) BLA and CNA OT-induced reduction in chow intake after deprivation, and 
on (B) BLA OT-induced reduction in palatable 10% sucrose or 0.1% saccharin 
solution intake. (C) Effect of BLA or CNA OT or IP 6 mEq LiCl (positive control) on the 
development of a conditioned taste aversion (CTA) to a novel KoolAid solution. OT 
injected at 1 µg in all applicable studies. */*** - significantly different from saline-
injected controls, P<0.05 and P<0.001, respectively. 
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Figure 3. Relative expression of OTr mRNA in the BLA (A) and CNA (B) of rats 
subjected to food deprivation or given access to a 0.1% saccharin solution (with 
chow available ad libitum) versus controls maintained on unrestricted access to  
chow. */** - significantly different from controls, P<0.05 and P<0.01, respectively. 
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5.	Chapter	Five	-	Concluding	remarks		
 
The plethora pf anorexigenic and anti-obesogenic effects associated with the action 
of oxytocin (OT) have generated significant interest in exploring potential therapeutic 
properties of this molecule in preclinical animal models as well as in human trials. 
Yet, in order to maximize the beneficial properties of OT in reducing excessive 
consumption and understand the occasionally conflicting data stemming from 
studies that employ distinct methodologies and research approaches, one has to take 
into account the diverse aspects of appetite affected by OT and the likely disparate 
central pathways that mediate these very specific effects.  
The ample evidence gathered in the current set of experiments confirms that OT 
promotes termination of ‘homeostatic’ aspect of consumption, i.e., intake for energy 
(Arletti, Benelli et al. 1989, Olson, Drutarosky et al. 1991, Olszewski, Wirth et al. 2001, 
Romano, Cassano et al. 2013, Katsurada, Maejima et al. 2014, Balazova, Krskova et 
al. 2016, Klockars, Brunton et al. 2017), and it also acts as satiety factor specific to 
sweet taste derived from carbohydrates as well as from non-carbohydrate 
sweetener, saccharin (Miedlar, Rinaman et al. 2007).  
I have shown here that LV, 4V, VMH, CNA and BLA administration of OT reduces 
standard chow-based meal size. This is very much in concert with the previous 
findings that lesioning of hypothalamic sites, including the PVN (the site of OT 
synthesis), and the interference in the functioning of bidirectional pathways between 
the hypothalamus and the hindbrain (where the OT receptor is highly expressed) lead 
to voracious feeding and obesity (Leibowitz, Hammer et al. 1981, Shor-Posner, Azar 
et al. 1985, Sims and Lorden 1986). Similarly, reversal of the obese and hyperphagic 
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phenotype caused by OT synthesis deficiencies, for example, due to genetic deletion 
of the OT encoding gene or due to developmental abnormalities in SIM-1 mutants, 
can be accomplished by supplementation of exogenous OT (Kublaoui, Gemelli et al. 
2008).  
It should be emphasized that OT protects internal milieu not only by controlling 
calorie in-out balance, but most importantly, by ensuring that physiological 
parameters arising from feeding, such as stomach distension, salt loading and 
chemical composition of plasma, do not exceed safe values (Brimble, Dyball et al. 
1978, Renaud, Tang et al. 1987, Olszewski, Waas et al. 2013).OT’s role is therefore 
far more critical for the survival of the organism than merely participating in the 
cessation of food intake once the energy needs have been met. In this context, it 
seems intuitive that the regulation of the ‘homeostatic’ aspects of energy intake 
would be the common outcome of activation of the OT receptor in all brain sites 
involved in appetite regulation. Indeed, the present data as well as studies published 
by other authors indicate that while OT decreases eating for palatability only through 
a subset of the brain regions that mediate OT’s effect on standard food, all areas 
associated with non-caloric control of feeding (particularly, reward), also regulate 
intake of homeostatically-relevant food loads regardless of their rewarding 
component (Olszewski, Klockars et al. 2010, Klockars, Levine et al. 2015, Olszewski, 
Klockars et al. 2016). Furthermore, activation of the OT receptor is essential for the 
development of proper behavioral avoidance mechanisms toward foods that have 
been identified as potentially tainted. This involvement of the OT receptor is 
especially significant in the process of achieving a threshold magnitude of activity in 
the CNA neuronal populations relevant to taste aversions (Olszewski, Waas et al. 
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2013). Thus, the functional importance of the OT receptor appears to be shifted 
toward mechanisms that guarantee safety of ingestive behavior. 
It was interesting to see that the hindbrain circuits are particularly sensitive to OT 
administration in terms of relaying the hypophagic action of this molecule. It is quite 
likely that hindbrain-acting OT targets those pathways that are reciprocal. Hence, it 
might simultaneously be enhancing activation of brainstem neurons that innervate 
the satiety systems in the hypothalamus as well as those brainstem cells that receive 
hypothalamic feedback aimed at supporting inhibition of food intake. In line with 
that, the generalized forebrain administration of OT (in the LV, as shown in Chapter 
2, and – previously – in the third ventricle (Arletti, Benelli et al. 1989, Blevins, 
Thompson et al. 2016)) and direct microinjections of the peptide in hypothalamic and 
extra-hypothalamic forebrain areas (VMH, CNA, and BLA, as shown in Chapters 3 and 
4) produce a slightly weaker hypophagic response than that observed after fourth 
ventricular injections (Chapter 2).  
Despite OT being effective in reducing consumption for energy in the vast majority 
of target areas studied in this project, it is clear that the presence of the OT receptor 
in a region linked with food intake control does not guarantee that this site indeed 
mediates OT-driven hypophagia. It was quite surprising to observe the lack of 
changes in feeding after administration of OT in the MPOA. After all, stimulation of 
other orexigenic and anorexigenic receptors in the MPOA, including those for 
galanin-like peptide, orexin A, or estrogen, results in changes in food intake (Dagnault 
and Richard 1997, Patterson, Murphy et al. 2006, Sarihi, Emam et al. 2015) 
Also, the MPOA is strongly involved in the regulation of energy balance and 
metabolism, most notably via processes related to thermoregulation and adjusting 
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energy intake/metabolism to challenges stemming from ambient environmental 
changes (Yu, Qualls-Creekmore et al. 2016).   
There is also one more reason why the lack of a functional relationship between 
MPOA OT and feeding comes as a surprise. Namely, the fact that the MPOA is a part 
of circuit responsible for affiliative and caregiving behaviors (a schematic 
representation of the network that incorporates the MPOA is shown in Figure 1) 
(Cittern and Edalat 2017). Importantly, it parallels one the key functions of OT. As a 
pleiotropic hormone, OT is also known to arbitrate affiliative and altruistic actions 
that might support food sharing (Gimpl and Fahrenholz 2001, Lee, Macbeth et al. 
2009). Smith et al. reported that intranasal OT administration amplifies huddling 
behavior between primate (Callithrix penicillata) partners while blockade of the OTr 
by an OTr antagonist, L-368,899 causes a substantial reduction in physical contact 
and prevented food sharing (Smith, Agmo et al. 2010). Other studies reveal that OT 
administration induces life-long pair bonding independent of mating in monogamous 
prairie voles (Microtus ochrogaster), reduces negligence and increases mother-infant 
bonding in prairie voles, humans, mice, rats, sheep and rhesus monkeys (Macaca 
mullata) (Olazábal and Young 2006)(Kendrick 2000, Liu and Wang 2003, Winslow, 
Noble et al. 2003, Galbally, Lewis et al. 2011). Although still very little is known as to 
whether OT has an ability to initiate early feeding termination in order to facilitate 
the act of sharing food with other individuals, we do know that the social status in a 
group and the social environment per se, do modify the magnitude of anorexigenic 
responses to OT in rats and mice (Olszewski, Allen et al. 2015, Herisson, Waas et al. 
2016, Olszewski, Klockars et al. 2016). Therefore, a complete insensitivity of feeding 
behaviors to activation of the OT receptor in the MPOA is quite puzzling. While it is 
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possible that the choice of male rats for our experiments might have affected the 
outcome, one should note that the OT receptor is present in this brain area in both 
sexes. Also, a decrease in the magnitude of OT-induced hypophagia in socially vs non-
socially fed animals in earlier studies was typically associated with group housing, 
hence, individuals tested alone (such as in the current experiments) should in fact be 
more sensitive to OT administration. 
. 
 
Figure 1. A schematic representation of the place of the MPOA in the immediate 
circuit responsible for triggering affiliative and caregiving behaviors. IPFC – inferior 
prefrontal cortex; mPFC – medial prefrontal cortex; Nac – nucleus accumbens; OFC – 
orbitofrontal cortex; VP – ventral pallidum; VTA – ventral tegmental area;  
 
Unlike the MPOA, another OT receptor expressing hypothalamic area studied in this 
project, the VMH, mediated a decrease in consumption for energy upon direct OT 
administration and this effect was reversed by a pre-treatment with an OT receptor 
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antagonist, L-368,899 (Chapter 3). Aside from the data generated in our laboratory, 
there is currently one other report that substantiates our findings (albeit by 
employing different food intake assessment scenarios) and it expands them onto the 
involvement of the VMH OT receptor system in the regulation of energy expenditure 
in voluntary exercise models (Noble, Billington et al. 2014). Combined, these 
independently generated sets of data strongly suggest that the VMH should be 
viewed as a site that integrates both feeding- and metabolism-related facets of OT’s 
action.  
The fact that intra-amygdalar OT (both in the CNA and BLA) suppressed deprivation-
induced intake of energy-dense standard chow (Chapter 4) is in agreement with the 
growing body of evidence showing that amygdala neurons not only express receptors 
for orexigenic and anorexigenic peptides (including, galanin, ghrelin and NPY), but 
also that their stimulation affects consumption of food even if this food is 
unpalatable (Beckman, Shi et al. 2009, Alvarez-Crespo, Skibicka et al. 2012). The 
amygdala, particularly the CNA, regulates glucose metabolism and adiposity, which 
is also in line with the known metabolic consequences of the generalized OT receptor 
stimulation (Mendes, Castro et al. 2017).  
While the results of my experiments elucidating the effects of site-specific OT on 
energy-driven (‘homeostatic’) aspects of consumption produced relatively uniform 
hypophagic responses, the studies focused on feeding for reward showed that only 
a small subset of consumption-related regions mediates macronutrient- and flavor-
dependent satiation. As mentioned above, MPOA OT did not affect any aspect of 
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consummatory behavior, but neither did OT acting at the VMH or CNA affect 
ingestion of palatable solutions.  
It seems somewhat intuitive that the stimulation of the OT receptor in the VMH, the 
site closely tied to the regulation of the metabolic state of the organism, does not 
modify intake of fluids whose calorie density is very low (sucrose, Intralipid) or null 
(saccharin), thus whose contribution to energy balance is minimal. However, that 
CNA OT (Chapter 4) does not affect consumption of tastants that produce a strong 
response of the mesolimbic reward system (and the amygdala is closely associated 
with it) clearly indicates that macronutrient- and flavor-specific satiety promoted by 
OT is the outcome facilitated by activity of relatively narrow subpopulations of the 
OT receptor that do not even span the entire reward system. This obviously does not 
negate the involvement of OT in decreasing appetite for sweets and carbohydrates 
(or reward, in general), but it rather points to an urgent need to identify discrete 
components of the reward circuit that are sensitive to OT stimulation in the context 
of feeding control. In fact, evidence linking OT and reward is substantial. OT terminals 
are localized in the proximity of reward-related neuroregulators such as dopamine 
and opioids (Sofroniew 1980, Bunzow, Zhang et al. 1995, Peris, MacFadyen et al. 
2017), Activation of the OT receptor in the NAcc core decreases methamphetamine-
seeking (Baracz, Everett et al. 2016) and attenuates methamphetamine- and alcohol-
induced conditioned place preference in rats (Baracz, Rourke et al. 2012, Bahi 2015). 
Food intake studies suggest that centrally acting OT decreases palatability- and 
macronutrient-dependent aspects of consumption, including opioid-induced 
overeating (Klockars, Levine et al. 2015). In particular, appetite for carbohydrates, as 
well as for saccharin, seems to be affected. Injections of OT into the VTA and NAcc 
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are effective in reducing intake of sweetened liquids (Melis, Melis et al. 2007, 
Herisson, Waas et al. 2016).  Mice treated IP with a blood-brain barrier-penetrating 
OT receptor blocker, L-368,899, elevate intake of carbohydrate and saccharin fluids, 
but not lipid-containing solutions (Herisson, Brooks et al. 2014). This result parallels 
increased preference for carbohydrates and saccharin in OT knockout animals 
(Miedlar, Rinaman et al. 2007). The effect of OT on palatability-driven ingestive 
behavior may be modified by caloric density of food, and therefore, by the energy-
related aspect of feeding. For example, OT treatments suppress ingestion of sugar-
free yet palatable high-fat laboratory pellets and genetic deletion of OT promotes 
overweight in rodents given access to a calorie-dense, high-fat diet (Wu, Xu et al. 
2012, Blevins, Thompson et al. 2016).  
In this project, however, only the BLA was found to be directly involved in the 
mediation of OT’s action on the intake for reward (Chapter 4). This is in line with the 
previously published reports defining the BLA as a site that integrates a complex 
rewarding value of stimuli (Wassum and Izquierdo 2015) and encodes emotional 
events characterized by sensory experiences (Balleine and Killcross 2006). BLA 
activation ensures the manifestation of conditioned responses (thus, responses that 
are based on either positive or negative sensory outcomes) (Gore, Schwartz et al. 
2015). Sugar exposure is known to affect BLA output (Packard, Di et al. 2017). The 
results presented herein allow us to expand our understanding of the breadth of the 
reward network that relies on the OT receptor in modifying consummatory 
responses to palatable tastants. Aside from the previously defined VTA and NAcc 
core (Melis, Melis et al. 2007, Herisson, Waas et al. 2016), we now can include the 
BLA in this circuit. This is much narrower than the aforementioned OT receptor-
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dependent CNS circuit that regulates eating for energy that includes the NTS, DMNV, 
VMH, NAcc, CNA, and BLA. 
 
Below are the key CONCLUSIONS stemming from the current doctoral research 
project: 
 
- Both lateral and fourth ventricular OT decreases consumption induced by one 
of the most potent orexigens known to date, butorphanol, but much lower 
OT doses are sufficient in the fourth ventricle. 
- Ventromedial hypothalamic OT receptor is involved in suppressing food 
intake motivated by energy needs, but does not affect consumption driven 
by reward. 
- The OT receptor in the medial preoptic area is unlikely to be involved in 
feeding control. 
- OT acting in the basolateral amygdala and central amygdala reduces appetite 
for energy. 
- Among the OT receptor populations expressed by the amygdala complex 
neurons, only the one present in the basolateral nucleus promotes 
suppression of palatability-driven ingestive behavior. 
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